TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into Euro 26 Million Financing of SpePharm

NEW YORK, MUNICH, Germany and AMSTERDAM, Netherlands, Aug. 21 /PRNewswire/ — Paul Capital Healthcare and SpePharm Holding, B.V., the pan-European specialty pharmaceutical company, today announced that they have entered into a euro 10 million revenue interest acquisition financing agreement to fund SpePharm’s acquisition of Dantrium(R) for Europe and certain other markets, from Procter & Gamble Pharmaceuticals. At the same time, TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare also announced the closing of a euro 16 million equity financing round to fund the ongoing growth of SpePharm Holding, B.V. SpePharm’s senior management will also participate in this current equity financing.

Jean-Francois Labbe, Chief Executive Officer of SpePharm, said:

“We are very pleased and excited by this major step in the development of our company. The investment made by Paul Capital Healthcare and the increased financial commitment of our founding investors TVM Capital and Signet Healthcare Partners will enable SpePharm to accelerate the implementation of its strategy to become a leading pan-European specialty pharmaceutical company. These transactions will provide SpePharm with the resources to complete the build up of our sales and marketing infrastructure, launch and promote our current product portfolio and acquire rights to additional products in areas of therapeutic interest.”

Mr. Labbe continued:

“Dantrium is a unique product used to treat malignant hyperthermia, a life-threatening reaction to certain gaseous anesthetics. Dantrium’s significant clinical benefit fits perfectly with SpePharm’s focus on hospital products that provide substantial medical and economic value. Procter & Gamble has established a solid commercial platform for Dantrium, and we believe that SpePharm has the strategy and resources to enhance the product’s commercial and clinical value.”

Dr. Ken Macleod, a partner at Paul Capital Healthcare, said:

“We believe that SpePharm’s management team has an effective strategy in place to become a leading specialty pharmaceutical company, meeting the needs of patients and physicians throughout Europe. Paul Capital Healthcare’s investment in SpePharm is consistent with the Fund’s mission to provide growth capital to innovative companies. The Fund’s investments in SpePharm will help the Company achieve its strategic objectives and underscores Paul Capital Healthcare’s commitment to tailoring financial vehicles that meet the unique needs of individual healthcare companies throughout the world.”

James Gale, a founding partner and Managing Director of Signet Healthcare Partners commented:

“We are delighted that Paul Capital Healthcare has joined the SpePharm investor group. The Fund’s financial commitment to the Company validates the substantial business opportunity for a pan-European specialty pharmaceutical company. SpePharm is taking a leadership position in the market for important therapeutic products with annual sales below euro 100M, which is underserved by large pharmaceutical companies. We believe that SpePharm is very well positioned to create value for patients, healthcare providers and the Company’s investors.”

Dr. Hubert Birner, General Partner of TVM Capital added:

“The investment by Paul Capital Healthcare will support SpePharm’s strategy of growth through active in-licensing and/or M&A. We believe that the extensive business development network provided by Jean-Francois Labbe and his team, Paul Capital Healthcare and the founding investors TVM Capital and Signet HealthCare Partners will yield numerous high value opportunities for SpePharm.”

About Paul Capital Healthcare and Paul Capital Partners

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.5 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $960 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at http://www.paulcapitalhealthcare.com/.

Paul Capital Partners manages $6.6 billion in equity capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London, Hong Kong, and Sao Paolo.

About TVM Capital GmbH

The TVM Capital Life Sciences Practice with euro 820 million ($1.26B USD) under management is one of the largest venture and growth investors in biotechnology and pharmaceuticals in Europe and the US, with a growing presence in Asia. The Life Sciences team builds on the expertise, experience, international approach and demonstrated success in more than 100 previous investments and almost 40 IPOs from our biotechnology and pharmaceutical portfolio of companies. The team combines long-standing international investment experience with pharmaceutical and biotech operating track records with extensive networks and knowledge regarding science, product discovery and development, manufacturing, marketing and distribution, international commercialization and finance. Twenty years of successful investing and value creation, in traditional early and late-stage venture as well as venture growth and growth capital, makes the TVM Capital Life Science Practice a unique partner for the needs of the biotechnology and pharmaceutical industry. Founded in 1983, TVM Capital is headquartered in Munich with offices in Boston and New York. More information: http://www.tvm-capital.com/.

About Signet Healthcare Partners

Signet Healthcare Partners was founded in 1998 with the establishment of the Corporate Opportunities Funds. Since 1998, we have organized three funds and completed investments in approximately 27 companies. The team, comprised of five professionals with principal offices in New York City, brings over 100 years experience of collective healthcare experience in the specialty pharmaceutical, medical device, private equity and investment banking businesses. For the past nine years, Signet Healthcare has maintained its dedicated focus to diversified healthcare investing — primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and the pharma services industries.

About SpePharm Holding, BV

SpePharm Holding, B.V. is a Dutch company with its registered office in Amsterdam, and its European operations based in Paris, France. SpePharm is an emerging pan-European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines essentially for the hospital markets. Particular areas of therapeutic interest are oncology, critical and supportive care. SpePharm was founded in September 2006 by Jean-Francois Labbe together with leading life science investment firms TVM Capital and Signet Healthcare Partners (part of the Sanders Morris Harris Group). Jean-Francois Labbe is a former top executive of Hoechst Marion Roussel and Parke Davis with over 30 years of experience in international pharmaceutical management. To date SpePharm has an established commercial presence in the UK, Germany, Italy, Benelux and the Nordic area where it is in the process of launching its first product, Loramyc(R), for the treatment of oropharyngeal candidiasis in immune-compromised patients.

For more information about SpePharm, please visit the web site at http://www.spepharm.com/.

   Contact Information    SpePharm Holding, BV               Tel: +31 (0) 20 491 96 02   Jean-Francois Labbe                Email: [email protected]    College Hill (SpePharm inquiries)  Tel: +49 (0) 89 5700 1806   Dr. Robert Mayer                   Email: [email protected]    Paul Capital Healthcare            Tel: +44 (0) 20 7514 0754   Ken Macleod, Partner               Email: [email protected]    Lazar Partners (Paul Capital       Tel:  +1-212-867-1762    Healthcare inquiries)   Stephanie Seiler                   Tel:  +1-206-713-0124                                      Email: [email protected]  

Paul Capital Healthcare

CONTACT: Jean-Francois Labbe of SpePharm Holding, BV, +31-20-491-96-02,[email protected]; or Dr. Robert Mayer, of College Hill, forSpePharm, +49-89-5700-1806, [email protected]; or Ken Macleod ofPaul Capital Healthcare, +44-20-7514-0754, [email protected]; or StephanieSeiler of Lazar Partners, for Paul Capital Healthcare, +1-206-713-0124,+1-212-867-1762, [email protected]

Web site: http://www.paulcapitalhealthcare.com/http://www.spepharm.com/http://www.tvm-capital.com/

UCSI Builds New Campus in N. Sembilan

UNIVERSITY College Sedaya International (UCSI) is forging ahead with a plan to build a new education township in Negri Sembilan.

The proposed township, covering 65ha in Bandar Springhill, will feature a 500-bed hospital and a Faculty of Medical Sciences in its first phase of development.

The faculty will offer programmes in medicine, pharmacy, nursing, optometry and physiotherapy.

UCSI entered into an agreement with West Synergy for the establishment of the township in February.

The project comes on the heels of a medical campus in Bukit Khor, Marang, Terengganu, where the first batch of 40 UCSI medical students enrolled.

The students are undergoing their final three years of clinical studies at Sultanah Nur Zahirah Hospital in Kuala Terengganu.

UCSI introduced the Doctor of Medicine degree programme in 2005, with the 40 students as the pioneer batch.

UCSI’s Faculty of Medical Sciences dean Professor Datuk Dr Roslani Abdul Majid said it was imperative that hospital facilities were available for students to do their practical.

At these hospitals, students are allotted hospital beds and they carry out a total patient work-up, which includes compiling information about patients and an analysis of the information.

At the School of Pharmacy, students are not only taught the fundamentals of becoming a pharmacist but also encouraged to expand their knowledge by carrying out research projects.

School of Pharmacy head Associate Professor Dr Yeong Siew Wei said the role of pharmacists would be expanded in the near future.

“Not only will pharmacists serve as a link in providing health information to the public, they will also be part of the process to conduct research and develop remedies for illnesses with other stakeholders in the health industry.”

School of Nursing head Associate Professor Jeya Devi Coomarasamy said the nursing profession had seen many changes.

She said nurses could upgrade their position by enrolling in a diploma or degree courses in nursing at the public and private institutions of higher learning.

Jeya Devi said one of the reasons UCSI offered the Bachelor in Nursing programme was because there was a demand for nurses.

“UCSI is the first institution of higher learning to obtain full accreditation for its nursing diploma and degree courses from the Malaysian Qualification Agency.”

Students from the Faculty of Medical Sciences organise health campaigns to educate the public on the importance of maintaining a healthy lifestyle.

This year, the Health Campaign with the theme “Say YES to A Healthier You!” was held at at a shopping complex in Petaling Jaway in June.

For details, call 03-91018880, email [email protected] or visit www.ucsi.edu.my

(c) 2008 New Straits Times. Provided by ProQuest LLC. All rights Reserved.

Doctors Warn of Earpiece Dangers

By MIRANDA C.R. WHITE

REDLANDS – Ear experts in Redlands say that people need to be careful with the earpieces for their new cell phones.

Because of traffic noise and other ambient noises, people turn the volume up on their devices, which could cause hearing damage.

The California law prohibiting use of hand-held cell phones while driving may make the roads safer, but doctors warn drivers using phones with earpieces to be careful of their hearing.

“There is a lot of ambient noise in a car, typically about 40 to 50 decibels, and most of us will unconsciously strain to hear, even with earpieces,” said Dr. John Arruda, an ear, nose and throat specialist at Redlands Community Hospital.

“So naturally, we turn up the volume as high as we can to make hearing easier and therein lies the danger.”

Arruda said the high volume could cause both acute and long-term hearing damage. He had other suggestions for using the new devices,so as to not damage one’s hearing.

“It’s better to use a microphone built into your car’s sound system or one that can be placed in the sun visor,” Arruda suggested.

Those who really need to use the earpiece should turn off the radio in the car and keep the windows rolled up to keep a lot of extra noise out, according to Dr. Frederick Jacobs, audiologist and ear, nose and throat specialist at Redlands Community Hospital.

“And keep the volume low enough to hear without straining,” Jacobs said.

Those who wear the earpiece inside the ear canal need to be sure it has no broken pieces. The pieces could hurt the skin inside the ear canal because the skin is very thin, according to Dr. Sharen Jeffries, an ear, nose and throat specialist at Redlands Community Hospital.

“Never push anything too far into the ear canal,” Jeffries said.

All three doctors said it is important to see a doctor if hearing is difficult with an earpiece.

E-mail Staff Writer Miranda C.R. White at [email protected]

(c) 2008 Redlands Daily Facts. Provided by ProQuest LLC. All rights Reserved.

Bus Stop: ; Arts Education

By Gzedit

OF COURSE, Kanawha County schools feel the pain of higher gas prices, just like everyone else. But it does not necessarily follow that cutting art-related field trips is the best way to balance the need to educate students with the need to cut costs.

Indeed, after Superintendent Ron Duerring decreed that future field trip approvals will favor those with strong ties to science, social studies, reading or math, the county’s transportation director couldn’t even say how much cutting art field trips might save the county.

County school officials have since softened their words on the subject. Each request will be considered individually, promised school board President Becky Jordon. The issue is expected to come up again at today’s school board meeting.

There is something wrong with this attitude that children should be allowed to view, hear or do art only if there is nothing better to do.

Kanawha County students are not only consumers of art. They produce it, as well. Performers at Chandler Elementary School’s magnet music program rely on other schools to provide the audience for their performances. What confidence and accomplishment might those Chandler students miss without that opportunity?

In a recent Sunday Gazette-Mail, David Wohl, dean of the College of Arts and Humanities at West Virginia State University, wrote that students who participate in the arts perform better academically.

The arts increase test scores and develop creative problem- solving, critical thinking, team building and communication.

Wohl, who is also director of the Charleston Stage Company and president of Arts Advocacy West Virginia, writes that arts teach about diversity and tolerance and keep students engaged.

Many defend art for art’s sake, for intangible benefits that are difficult to measure. But the National Endowment for the Arts offers another reason to support art instruction – working artists actually make up a substantial fraction of the American economy. At about 2 million people, they are one of the largest classes of workers and only slightly smaller than the active-duty and reserve U.S. military.

Not only do artistic pursuits nourish other fields and professions, they have become economic components on their own.

The problem in Kanawha County is not that the superintendent or school board members want to save money on transportation. The problem is in thinking that it is OK to simply lop off arts field trips, any more than it would be OK to unilaterally ban all math, science or football trips.

(c) 2008 Charleston Gazette, The. Provided by ProQuest LLC. All rights Reserved.

If You Can’t Say Something Nice, E-Mail It

By BELINDA M. PASCHAL DDN CYBER-COLUMNIST

Earlier this week, a buddy and I were bemoaning the fact that technology — specifically electronic communication — is turning human interaction into a thing of the past. Fittingly, our conversation took place via e-mail.

Gone are the days of opening my mailbox to find a friend’s kid gaptoothily grinning up from a school picture paper-clipped to a dogeared letter chronicling the events of the past year in rambling fashion. Nowadays, I receive e-mails with links to personal pages showcasing 1.3-megapixel photos of baby Jaden’s new tooth or streaming video of little Madison’s debut in the kindergarten production of “High School Musical.”

It’s getting so that couples “date” six months before they even meet in person and “how we met” stories are peppered with phrases like “cyber-dating” and “hookup.com.”

Now, not only can you whisper sweet nothings via e-mail, you can pass along not-so-sweet somethings as well. Got a co-worker who’s a bit, um, “aromatic,” and you don’t know how to tell him? If wearing a gas mask doesn’t clue him in and you’re not comfortable giving him a gift basket from Bath & Body Works, then NiceCritic.com is the way to go.

The site, which launched on July 4, calls itself “the anonymous way to send a helpful message” and allows you to send e-mails that can’t be traced to you or your computer. In other words, it’s a nice way to say mean things without taking responsibility. Site developer Erik Riesenberg got the idea when a friend who’d had several drinks, informed him that he really needed to trim his nose hair.

While getting liquored up is one way of gaining the courage to speak your mind, it’s bad for your liver and your safety. Plus, it’s frowned upon at most workplaces. Instead, consult NiceCritic.com, where the “helpful messages” fall into several categories, including:

Personal Hygiene: “A breath mint would be beneficial today” sounds so much nicer than, “Dude, your breath is kickin’ like Jackie Chan!”

Appearance: “It seems like your thong is showing” is a tip for which any colleague would be grateful. Unless she’s an exotic dancer.

Office Behavior: If your glazed expression and gaping yawn doesn’t get your point across, try this gentle hint: “Stories about your kids are not as interesting as they used to be.”

Cubicle Critic: “Please be courteous with the copier” is more discreet than publicly proclaiming, “You left these photocopies of your butt on the Xerox last night, Bob. Nice tattoo.”

Neighborly Suggestions:

“Please remember to close your blinds/curtains in the evening” is infinitely more courteous than, “Man, your wife is NOT aging well!”

Other categories are “Thoughts for Schoolmates,””Sports Etiquette,” and “General Behavior,” which features my personal favorite, “You don’t release your hug in a timely manner.” If anyone decides to send me a NiceCritic.com message, I can only hope it’s something the “Anonymous Praise” section rather than a heads-up that, “There seems to be some back-hair poking out of your shirt collar.”

AN E-MAIL WOULD BE BENEFICIAL TODAY:

[email protected]

(c) 2008 Dayton Daily News. Provided by ProQuest LLC. All rights Reserved.

The Journal: World-Class Research Will Benefit Us All

THE breakthrough announced today by the North East England Stem Cell Institute and Durham University offers, first and foremost, a ray of hope for patients suffering from the most aggressive forms of bowel cancer.

By potentially enabling medical staff to pinpoint those most likely to benefit from chemotherapy, it could help to ensure that patients receive the most appropriate treatment available.

It is the kind of research capable of profoundly affecting for the better the lives of thousands of people living with this terrible disease.

Therefore, it is also proof of the tangible benefits now being generated as a result of the work of the institute and its partners in the region, be they in academia or frontline health services.

The North East is now building upon its long held reputation for first class medical expertise.

Newcastle’s designation as a Science City will help to nurture this, as a community of scientists develops which has the connectivity and competitive edge which will drive forward research.

From time to time this work will be controversial, as we have seen with the institute’s role in the development of human-hybrid embryos.

But it will also yield undoubted benefits that will be welcomed far beyond the confines of the region.

(c) 2008 The Journal – Newcastle-upon-Tyne. Provided by ProQuest LLC. All rights Reserved.

GP Barred on Eve of Retirement

By CAROLINE INNES

A MERSEYSIDE doctor was suspended just weeks before hewas due to retire.

Dr Javaid Iqbal, of the Halewood Health Centre, was barred from practising on July 24 by the General Medical Council (GMC).

He was due to retire on September 1 after 43 years’ service within the NHS.

The GMC today confirmed Dr Iqbal, of Woolton, was suspended pending an investigation into complaints against him.

Details of the allegations and who made them have not been revealed.

But a GMC spokesman said: “The interim orders panel considered it was necessary for the protection of members of the public, in the public interest and in Dr Iqbal’s own interest to make an order suspending his registration for 18 months.”

Dr Iqbal, who trained at Pakistan’s Punjab university, shares the Roseheath Drive practice with his wife, Dr Dure Iqbal.

No action is being taken against her and she continues to practise there.

Today, health officials vowed not to let patient care suffer as a result of Dr Javaid Iqbal’s suspension and said a new doctor will take over on September 1.

A spokesman for Knowsley primary care trust said: “We can confirm Dr Iqbal was suspended by the interim orders panel of the GMC for a period of 18 months.

“We have been in contact with Dr Iqbal’s practice to ensure the needs of his patients are met while he is suspended.”

Dr Iqbal said the GMC panel sat while he was on holiday and he returned to find he had been suspended.

He has taken legal advice about the lawfulness of the panel sitting in his absence.

Dr Iqbal said: “I am so upset about all of this. I would give my right arm for my patients.

“I believe the primary care trust has a vendetta against me because I have been on at them about the way they run things.

“It will be shown I have done nothing but try to do my best for my patients and my name will be cleared.”

The PCT would not comment on his claim.

[email protected]

(c) 2008 Liverpool Echo. Provided by ProQuest LLC. All rights Reserved.

Children Pull Their Way in Tractor Event

Children’s Pedal Tractor Pull

Listed by age and order of finish.

4-year-olds – Boys: Trent Ryan, John Knockle and Mitchell Weber. Girls: Jasmyn Hoeger, Kylee Hedrick and Alyssa Lindecker.

5-year-olds – Boys: Ray Runde, Kyle Felderman and Trevor Schuman. Girls: Taylor Cota, Kaylee Schueller and Victoria Walker.

6-year-olds – Boys: Tim Gonau, Luke Althaus and Levi Ryan. Girls: Emma Powers, Alesha Veach and Ashlyn Habel.

7-year-olds – Boys: Levi Pfab, Travis Tucker and Logan Wingert. Girls: Whitney C., Sara Langmeier and Kaylee Waterhouse.

8-year-olds – Boys: Travis Wolf, Luke Millius and Dalton Rolling. Girls: Janelle Klein, Sidney Valentine and Katie Fitzpatrick.

9-year-olds – Boys: Devon Dean, Colin Donovan and Sam Vorwald. Girls: Allison Tucker, Abby Hoefler and Katie Niklasen.

10-year-olds – Boys: Jacob Fitzpatrick, Cory Wernimont and Jacob Osterberger. Girls: Kaitlyn Reusch, Alyssa Dougherty and Alexi Avenarius.

(c) 2008 Telegraph – Herald (Dubuque). Provided by ProQuest LLC. All rights Reserved.

MPS Must Pay Over $450,000 in Legal Fees in Special-Needs Lawsuit

By DANI McCLAIN

Milwaukee Public Schools must pay just more than $450,000 to the legal staff representing plaintiffs in a class-action suit over how the district serves students with special needs, a federal judge has ordered.

The order Friday followed a ruling in June that MPS must do more for special-needs students, including assessments for children who might need services and interventions for students who have a high number of suspensions and for those who have failed a grade.

Staff at Disability Rights Wisconsin sought $1.2 million in attorneys’ fees incurred in arguing the suit through the end of September, when the court decided that MPS and the state Department of Public Instruction had violated federal special education law.

DPI, initially a co-defendant, was dismissed from the case after it settled with the organization this spring. The state agency agreed to pay $475,000 in attorneys’ fees as part of the settlement.

The court has now ordered that MPS pay $459,124.

In petitioning the court, Disability Rights Wisconsin argued that its staff of four attorneys, five paralegals and seven law clerks put in roughly 7,400 hours of work on the case over more than six years.

Considering options

In a response e-mailed Friday, school officials offered little on the latest development in the suit.

“MPS continues to provide quality services to children with special needs,” wrote Patricia Yahle, the district’s director of special services. “The Board is considering its options.”

The settlement with DPI, announced in March, included the appointment of an outside authority, paid by the state agency, to monitor MPS compliance with state and federal special education law and establish standards for MPS.

MPS did not enter into the agreement and issued a statement calling DPI’s decision a disappointment because of the tax increase that district officials say will result for taxpayers.

Still ahead is a trial in November on issues such as whether MPS might be required to provide compensatory damages to anyone who was denied adequate special education in 2000, the starting point for the lawsuit.

Copyright 2008, Journal Sentinel Inc. All rights reserved. (Note: This notice does not apply to those news items already copyrighted and received through wire services or other media.)

(c) 2008 Milwaukee Journal Sentinel. Provided by ProQuest LLC. All rights Reserved.

Liver Transplant Program Established At Montefiore

NEW YORK, Aug. 20 /PRNewswire-USNewswire/ — Patients who suffer from severe liver disease and need a liver transplant will no longer have to seek that highly specialized surgery and critically important follow-up care outside the borough of the Bronx. Area patients and their families now have access to this high-quality care locally, without having to travel long distances, as a result of the New York State Department of Health’s approval of the first and only liver transplant program in the Bronx, at Montefiore Medical Center (http://www.montefiore.org/).

“The liver transplantation program at Montefiore Medical Center fills a significant, unmet medical need for people who live in the Bronx and suffer from end-stage liver disease,” said Steven M. Safyer, M.D., president and CEO of Montefiore.

“The Bronx has one of the highest rates of liver disease in the country and the highest rate of liver disease in New York State,” said Dr. Safyer. “Until now, patients in the Bronx and surrounding areas who had liver disease had to travel outside of the borough to receive care, which was an additional burden on them and their families.

“Our liver transplant program now allows these patients to receive be cared for locally closer to home, by a team of professionals, at a center with an incredible amount of experience and expertise in all aspects of liver care,” said Dr. Safyer.

The liver transplant program is part of the Montefiore-Einstein Liver Center and is supported by a research component from Albert Einstein College of Medicine’s National Institutes of Health-funded Liver Center.

“We have a world class team of surgeons and liver specialists with a wide range of experience in treating and researching severe liver disease,” said Milan Kinkhabwala, M.D., chief of transplantation and director of abdominal organ transplantation at Montefiore. “More than 120 Bronx patients were waiting for liver transplants in 2007, and approximately 50 local residents had no choice but to seek a liver transplant outside the borough last year,” said Dr. Kinkhabwala.

While there are more than 2,300 people statewide currently waiting for a liver transplant, statistics for New York State show that risk factors for liver disease are significantly higher for residents of the Bronx when compared to other areas of the state.

Doctors at Montefiore believe there is actually 10 times the recorded number of people in the Bronx with serious liver problems. Montefiore’s unique capabilities as an academic medical center help address these problems through community-based outreach, patient and physician education and the patient care provided by a nationally recognized team of liver specialists. Thousands of patients suffering from serious liver diseases including Hepatitis C, cirrhosis and cancer are treated annually at Montefiore.

“We have found there is a greater rate of alcohol use, intravenous drug use and confounding variables like malnutrition and diminished access to health care here in the Bronx,” said Paul Gaglio, M.D., a nationally known liver expert and medical director of Montefiore’s Liver Transplant Program. “The number of hospitalizations for liver-related diagnoses in Bronx-area hospitals has increased substantially, magnifying the importance of having an easily accessible local liver transplant center in the Bronx,” said Dr Gaglio.

In addition to liver transplantation, Montefiore has programs in adult and pediatric heart transplantation, adult and pediatric kidney transplantation and bone marrow transplantation.

Montefiore Medical Center encompasses 124 years of outstanding patient care, innovative medical “firsts,” pioneering clinical research, dedicated community service and ground-breaking social activism. A full-service, integrated delivery system caring for patients in the New York metropolitan region and beyond, Montefiore is a 1,491-bed medical center that includes: four hospitals — the Henry and Lucy Moses Division, the Jack D. Weiler Division, the North Division and The Children’s Hospital at Montefiore; a large home healthcare agency; the largest school health program in the U.S.; a 21-site medical group practice integrated throughout the Bronx and Westchester; and, a care management organization providing services to 179,000 health plan members.

In 2008, The Children’s Hospital at Montefiore (http://www.montekids.org/) ranks as one of “America’s Best Children’s Hospitals” in US News & World Report’s prestigious annual listing. Montefiore is ranked by the Leapfrog Group among the top one percent of all U.S. hospitals based on its strategic investments in sophisticated and integrated healthcare technology.

Montefiore is committed to meeting the healthcare needs of the future through medical education and manages one of the largest residency programs in the country. Montefiore is The University Hospital and Academic Medical Center for Albert Einstein College of Medicine and has an affiliation with New York Medical College for residency programs at the North Division.

Distinguished centers of excellence at Montefiore include cardiology and cardiac surgery, cancer care, tissue and organ transplantation, children’s health, women’s health, surgery and the surgical subspecialties. Montefiore is a national leader in the research and treatment of diabetes, headaches, obesity, cough and sleep disorders, geriatrics and geriatric psychiatry, neurology and neurosurgery, adolescent and family medicine, HIV/AIDS and social and environmental medicine, among many other specialties. For more information, please visit http://www.montefiore.org/ or http://www.montekids.org/.

Montefiore Medical Center

CONTACT: Steven Osborne, [email protected], or Mike Quane,[email protected], +1-718-920-4011, both of Montefiore Medical Center

Web Site: http://www.montefiore.org/http://www.montekids.org/

Prominent Urologist, Peter J. Muench, M.D., Recommends Penile Implant Surgery Over Viagra(R) for More Extreme Erectile Dysfunction (ED) Cases

There’s no question that Viagra(R) and drugs like it provide the best option for men with mild to moderate cases of erectile dysfunction (ED). It’s been around for 10 years now and oral medications work well for the not-so-impaired. Peter J. Muench M.D., a urologist with Delaware Urologic Associates (DUA) in Newark, Delaware says improvements in penile implants make them the way to go for anyone with serious dysfunction.

Tough cases of ED are widespread among prostate cancer patients. Studies show that patients recovering from prostate surgery who get immediate post-operative treatment of either nightly Viagra(R) or thrice-weekly Caverjet(R) (PGE injection) have a much greater return of spontaneous erections at 3 months compared to those who receive no post-operative treatment. However, some people don’t respond to oral erectile dysfunction medications and the FDA has required Upjohn to pull Caverjet Impulse(R) from the market while its packaging is being updated.

For patients with serious ED, Dr. Muench believes penile implants are the best solution. According to Muench, “Implants have higher patient and partner satisfaction rates than any other therapy.” Penile implants provide maximum rigidity, durability and concealability, and with new improvements, the risk of infection is quite low. Implant makers Coloplast and AMS both now make models that are coated with antibiotics, similar to newly improved cardiac stents. This new technology has greatly reduced the risk of infection.

Dr. Muench can’t overstate the benefits of penile implants for the patients with severe ED: “For a patient with severe erectile dysfunction, who’s bottomed-out in terms of erectile function, helping him by implanting a penile prosthesis allows him to immediately perform not only better than his peers, but, in many respects, also even better than he himself ever had in his prime. Because his implant stays erect until he deflates it, he needn’t ever worry about not lasting until his partner is satisfied or climaxing too soon.”

About Dr. Muench and Delawareurologic.com

Peter J. Muench, M.D. is medical Director of Delaware Urologic Associates (DUA) in Newark, Delaware. DUA specializes in the diagnosis and treatment of male and female urologic disorders, using minimally invasive procedures. For more information about Dr. Muench’s state-of-the-art urology treatment options, including penile implants and medications for erectile dysfunction, please don’t hesitate to call his office at 302-266-7577.

 Contact: Peter J. Muench, M.D. Delaware Urologic Associates 302-266-7577  

SOURCE: Delaware Urologic Associates

Medinet Starts Commercialization of Novel Cancer Immunotherapy Technology in Japan Utilizing MaxCyte’s Cell Loading System

GAITHERSBURG, Md. and YOKOHAMA, Japan, Aug. 20 /PRNewswire/ — MaxCyte, Inc. and Medinet Co., Ltd. announced today that Medinet will begin commercializing a novel cell engineering approach, utilizing MaxCyte’s cell loading technology, on its cancer immunotherapy services in Japan. The new approach to cancer immunotherapy is expected to achieve increased efficacy compared to the method which Medinet has been providing. In August of 2007, both parties signed an exclusive license, development and supply agreement to use MaxCyte’s proprietary cell loading system to support clinical studies and commercialization of Medinet’s cancer immunotherapy service in Japan. Under terms of the agreement, MaxCyte provides the exclusive right to utilize its proprietary technology in the closed-system manufacturing of Medinet’s immuno-cell therapy service in multiple cell processing centers across Japan. The manufacturing process of the immunotherapy will be based on optimized protocols developed under the MaxCyte-Medinet collaboration announced in August, 2006.

About Medinet

Medinet is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, Medinet provides medical institutions with advanced technologies and know-how in: cell processing and culturing, quality control, and facility management with respect to the immuno-cell therapy. Medinet has extensive experience in autologous cell processing; with more than 7,500 cancer patients treated in actual clinical practice through more than 60,000 cell therapy manufacturing processes. Medinet continues to invest in R&D to improve cell processing technologies in an effort to increase efficacy in collaborative clinical studies with university hospitals and medical institutions. Medinet went public in October, 2003 on the MOTHERS, Tokyo Stock Exchange.

   For more information, visit http://www.medinet-inc.co.jp/english/    About MaxCyte   

MaxCyte is the leader in providing clinical/commercial cell modification technologies and unparalleled expertise to the global leaders in cell-based therapies. MaxCyte’s cell transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases.

MaxCyte’s licenses its cell modification technology to companies developing cell-based therapies and sells instruments and disposables to leading biopharmaceutical companies for drug discovery. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of Chronic Lymphocytic Leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than a dozen commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER). Building on its core technology and relationships, new opportunities are being pursued in the development of first-in-class targeted therapies for cancer, autoimmune and infectious diseases. MaxCyte intends to develop these programs to the proof-of-concept stage and then enter into co-development agreements with biopharmaceutical companies.

For more information, visit http://www.maxcyte.com/.

MaxCyte, Inc.

CONTACT: Kiyoshi Yokokawa of Medinet Co., Ltd., +81.45.478.0041; orDouglas A. Doerfler of MaxCyte, Inc., +1-301-944-1620

Web Site: http://www.maxcyte.com/http://www.medinet-inc.co.jp/english

Sinobiomed Corporate Update

Sinobiomed, Inc. (“Sinobiomed”, or “the Company”) (OTCBB: SOBM) is pleased to announce the following business updates:

Malaria Vaccine

The Company is in late stage discussions with Mahidol University in Bangkok, Thailand, to initiate Phase IIb clinical trials of its recombinant malaria candidate vaccine (PfCP2.9) under Mahidol’s supervision. The Company expects to begin trials before the end of Q3.

Recombinant Batroxobin (rBAT)

The Company is currently conducting Phase IIb clinical trials of its anti-bleeding agent, recombinant Batroxobin (rBAT), with multiple test groups totalling 328 patients in seven hospitals in China. Results are expected before year’s end. Should the product proceed to Phase III clinical trials, it is expected that international governments and organizations would show significant interest. The Company has already received indications of interest from global pharmaceutical companies for joint development, marketing and production.

Native batroxobin, extracted from pit viper venom, is the world’s most prescribed biological anti-bleeding agent. Since rBAT is produced through genetic engineering, it reduces the risk of biological contamination and neurotoxicity that have been associated with native batroxobin.

Skincare and Cosmetics Products

The Company’s skincare and cosmetics range, launched in early 2007, is achieving significant success. Shanghai Wanxing Bioscience Cosmetics, 50.33% owned by Sinobiomed, is expected to generate sales of more than US$3 million over the coming twelve months with anticipated gross profit margins greater than 70 percent.

Shanghai Wanxing Bioscience Cosmetics has developed a breakthrough skin rejuvenation product that utilizes rh-aFGF, a patented recombinant therapy developed by Sinobiomed that is highly effective in the treatment of diabetic ulcers and burns, in a proprietary formula. Consumers can now purchase a skincare product with an ingredient that is clinically proven to promote healing, which the Company believes helps support healthy and younger looking skin. The product line, with more than 100 SKU’s, is sold exclusively through a home shopping channel under the brand name “Kaiying”. This initiative is a natural extension of the Company’s ability to commercialize biotechnology and successfully penetrate consumer channels.

Shanghai Wanxing Bioscience Cosmetics is currently in discussions with other home shopping channels in China and other emerging markets such as India and Southeast Asia to carry and promote Kaiying’s range of skincare and cosmetic products.

Other developments

The Company is conducting research and development in conjunction with several medical universities and expects to have an additional four new products in the pipeline by years end.

ABOUT SINOBIOMED INC.

Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company’s products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.

 SINOBIOMED INC. LANE 4705, NO. 58, NORTH YANG GAO RD. PUDONG, NEW AREA SHANGHAI, 201206 CHINA PHONE: 86-58993708 / FAX: 86-58993709 

FORWARD LOOKING STATEMENTS: This news release may include “forward-looking

statements” regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.

 Contacts: Sinobiomed Inc. Investor Relations (718) 502-8801 or Toll Free: 1-866-588-0829 Email: [email protected] Website: www.sinobiomed.com

SOURCE: Sinobiomed Inc.

Research Priorities Askew

Nearly 73,000 Americans died of Alzheimer’s Disease in 2006, the most recent year for which numbers are available. By comparison, about 14,000 died of AIDS. And yet the amount of money spent on Alzheimer’s research by the federal government is a fraction of the $2.9 billion it spends on HIV/AIDS research.

The Centers for Disease Control estimates that 56,300 Americans were newly infected with HIV in 2006, while there were more than 411,000 new cases of Alzheimer’s. And yet, federal funding for Alzheimer’s research has been stuck at about $650 million a year for the past five years, compared to the $2.9 billion for HIV/AIDS.

I’m not suggesting that funding for HIV/AIDS research be curtailed. But it is obvious from these numbers that the federal government’s priorities are out of whack when it comes to dealing with a far, far more serious threat to the country’s population and its health-care infrastructure and resources than AIDS represents. In relative terms, the federal government is not exactly ignoring Alzheimer’s, but it is certainly not taking it as seriously as it should. Get this: Federal per-patient spending on West Nile Virus research is $15,564 annually while per-patient spending for Alzheimer’s is a measly $124.

Alzheimer’s is the degenerative, always-fatal brain disease that destroys its victims’ lives before it takes them. Experts predict that, as the Baby Boom generation ages, the number of cases diagnosed each year will increase to half a million by 2010 and almost a million by 2050.

Alzheimer’s and other dementias account for about a third of the $450 billion now spent on Medicare beneficiaries. In just 25 years, one expert told Congress, Alzheimer’s costs will approach the entire amount now spent on Medicare. In other words, Alzheimer’s-related costs will overrun the Medicare system, and Medicaid as well.

The cost will not be paid in public dollars alone. Seven of 10 Alzheimer’s sufferers live at home and 75 percent of the care they receive is provided by loved ones, at an average cost to families of $19,000 a year. When the patient can no longer live at home, families face paying half or more of the cost of a nursing home or assisted-living center. The disease destroys not only its victims’ brains and lives, it destroys their families’ financial stability.

In the great majority of cases Alzheimer’s manifests itself after age 65. So even if research does not immediately produce a cure, discoveries of drugs and therapies that delay the onset of the disease by a few years will greatly reduce the number of people who experience it — and will prevent much of the staggering cost to society. There have been promising discoveries already, including some drugs that temporarily delay early symptoms. But much more is needed.

One reason that Alzheimer’s research funding has lagged behind other diseases is that it does not have a vocal constituency. Alzheimer’s victims can’t speak out to Congress about the disease because, eventually, they can’t speak. There are no survivors to tell their stories because no one survives it. Families of victims are too busy and too wiped out emotionally and financially caring for their loved ones to do much advocating.

So it is up to Congress to wake up and do something to head off the debacle that looms in the not-too-distant future. Funding for Alzheimer’s research, compared to spending on other diseases, ought to reflect the huge threat that it poses to the nation’s health and welfare. A good start would be at least $1 billion a year for research.

David Averill, 581-8333

[email protected]

Originally published by David Averill, 581-8333.

(c) 2008 Tulsa World. Provided by ProQuest LLC. All rights Reserved.

Walgreen’s First for Nationwide Launch of Pediatric Electrolyte Strips From Healthsport, Inc.

WOODLAND HILLS, Calif., Aug. 20, 2008 (GLOBE NEWSWIRE) — HealthSport, Inc. (OTCBB:HSPO) is pleased to announce that Walgreen Co. is the first national drug store chain to carry HealthSport’s pediatric electrolyte strips. Walgreen’s, with more than 6,000 retail stores across the country, is selling the product under its own private label and providing customers with a choice between two popular flavors: Grape and Orange. The pediatric electrolyte strips, developed and manufactured by InnoZen, Inc. (a wholly owned subsidiary of HealthSport, Inc.) and distributed by Unico Holdings, Inc., will be available nationwide in the baby nutrition section of Walgreen’s drug stores before September 1, 2008.

“Unico has done an amazing job of introducing our pediatric electrolyte strips to the drug store community, as well as explaining the benefits of our technology over the competition. Walgreen’s marks the first national drug store chain to carry our pediatric electrolyte strips, and we are experiencing great success in working with Unico to procure other major national and regional clients. This product represents a landmark addition to a pediatric category that has not seen substantial innovation in decades,” stated Rob Davidson, Chairman, HealthSport, Inc.

Pediatric electrolyte strips are specifically formulated for children to quickly and safely replenish electrolytes and aid in fluid retention. The strips are a safe and effective means to replace lost electrolytes associated with symptoms of flu, diarrhea, vomiting or extreme climates. Pediatric electrolyte strips utilize a superior system of electrolyte delivery through partial absorption via the oral mucosa. This enables the electrolytes to be delivered quickly and efficiently into the body, thereby putting less strain on the ailing G.I. tract. Pediatric electrolyte strips are also sugar-free, making them an attractive choice for diabetic children or for parents who are concerned with adding sugar to their children’s diet.

About HealthSport, Inc.

HealthSport, Inc. (http://healthsportinc.com) is a fully integrated developer, manufacturer and marketer of unique and proprietary branded and private label edible film strip nutritional supplements and over-the-counter drugs. The Company owns three subsidiaries — Enlyten, Inc., InnoZen, Inc. and Cooley Nutraceuticals, Inc. Enlyten (http://www.enlytenstrips.com) was created to market and distribute HealthSport’s products. InnoZen, Inc. (http://www.innozen.com), is the preeminent formulator, developer and manufacturer of edible film strips that deliver drug actives through buccal (between the cheek and gum) absorption. InnoZen’s proprietary edible film strip delivery technology is superior to any other competitive edible film strips currently available on the market. InnoZen has five patents pending and has developed numerous trade secrets which it incorporates in the development and manufacturing process of edible film strips. The Company’s current products are sold through its wholly-owned subsidiary, Enlyten, Inc.

About Unico Holdings, Inc.

Unico Holdings Inc., (http://www.unico-holdings.com) is a leading independent manufacturer of private label health and personal care products. Headquartered in Lake Worth, Florida, Unico’s product offering includes pediatric electrolyte solutions and personal care products. The Company markets its products through numerous sales channels, including large retail merchandisers, drug store chains, grocery stores and pharmaceutical distributors. Unico’s customers include most of the largest retailers and distributors in the U.S. in each of these sales channels. As part of its on-going expansion strategy, Unico will look to increase opportunities in manufacturing, developing and purchasing additional product lines while continuing to expand its customer base.

Forward-Looking Statements in this news release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only, and is not an offer or solicitation to buy or sell the securities.

This news release was distributed by GlobeNewswire, www.globenewswire.com

 CONTACT:  HealthSport, Inc.           David Reid           (818) 593-4880 

WellPoint NextRx and Blue Cross & Blue Shield of Rhode Island Will Enhance E-Prescribing Capabilities for RI Physicians

INDIANAPOLIS, Aug. 20 /PRNewswire/ — WellPoint NextRx, an independent pharmacy benefit management (PBM) company and the nation’s largest health-plan-owned PBM, announced today that SureScripts-RxHub connectivity is available to physicians in Rhode Island through Blue Cross & Blue Shield Rhode Island (BCBSRI) effective August 16, 2008. The connection to SureScripts-RxHub network is part of WellPoint NextRx’s e-prescribing strategy to reduce the time physicians spend managing prescriptions while saving members money. It also supports BCBSRI’s ongoing efforts to encourage adoption and use of electronic health records by physicians.

“Approximately one in three Americans carry a Blue Cross and/or Blue Shield card. Partnering with Blue Cross and Blue Shield plans is one way in which we can combine our expertise and implement new programs to positively impact the cost and quality of care that members receive,” said Renwyck Elder, president of WellPoint NextRx. “WellPoint NextRx is consistently identifying new programs that offer health plan members access to affordable, quality medications. We’re pleased to be working with BCBSRI to connect physicians, including those treating BCBSRI members, to critical decision support information at the point of care to help manage the patients’ use of medications and counsel patients on safe and affordable choices.”

The connection to SureScripts-RxHub allows NextRx to electronically link with physicians/providers who e-prescribe, providing valuable real-time pharmacy information before prescriptions are written, thereby helping to reduce errors and increase physician effectiveness. Before an authorized physician or provider prepares an e-prescription for a BCBSRI member, with patient consent, immediate eligibility and formulary information will be provided from NextRx. In addition, medication history can also be provided to physicians during the prescribing process.

“We are making every effort to promote the adoption and use of electronic health records by Rhode Island physicians,” said Jim Purcell, president and CEO, BCBSRI. “We believe that making e-prescribing easier will further encourage its use, which will directly benefit our members.”

In 2006, the state of Rhode Island finished first in the nation as part of the first ever nationwide ranking of electronic prescribing activity, earning the state the SafeRx Award. Earlier this year, NextRx completed a pilot program launched by BCBSRI for increasing the use of specific generic over- the-counter medications. The OTC Options Program was designed by NextRx in response to BCBSRI’s desire to help members save money on medications to treat common ailments such as allergies.

SureScripts-RxHub operates a low-cost utility that facilitates the secure exchange of e-prescriptions and prescription information nationwide. NextRx was first connected to SureScripts-RxHub in late 2006.

WellPoint NextRx is a service mark of WellPoint, Inc. Services are provided by a WellPoint PBM (either NextRx Services, Inc. or NextRx, LLC, as applicable). WellPoint NextRx is a division of WellPoint, Inc.

About WellPoint NextRx

WellPoint NextRx is a progressive pharmacy benefit manager (PBM) helping health plans, employer groups and third party administrators target the reduction of total health care costs and improve health outcomes. NextRx provides extensive PBM services including claims processing, clinical and disease management programs, retail network, mail and specialty pharmacy, customer service, and rebate management. With roots that date back to the 1980’s, NextRx has years of experience in providing all of these fundamental services. WellPoint NextRx is a division of WellPoint, Inc. Services are provided by a WellPoint PBM (either NextRx Services, Inc. or NextRx, LLC, as applicable). Visit http://www.wellpointnextrx.com/.

About SureScripts-RxHub

SureScripts-RxHub gives healthcare providers secure, electronic access to prescription information that can save their patients’ lives and reduce the cost of healthcare for all. Available during emergencies or routine care, SureScripts-RxHub’s network is used by physicians, physician assistants and nurse practitioners nationwide to exchange health information and prescribe without paper. The next time you or anyone you know goes for a checkup and your healthcare provider takes out their pad and pen to write a prescription, take the opportunity to ask them for an e-prescription instead. For more information go to http://www.surescriptsrxhub.com/.

About Blue Cross Blue Shield Rhode Island (BCBSRI)

Blue Cross & Blue Shield of Rhode Island has been the state’s leading health insurer for more than 69 years and now covers more than 680,000 members. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

WellPoint NextRx

CONTACT: Lisa Greiner, Comprehensive Health Solutions (CHS)Communications Director, +1-212-476-7011, [email protected]; ChrisMedici, Chief Communications Officer, Blue Cross & Blue Shield of RhodeIsland, +1-401-459-5283, [email protected]; Rob Cronin,SureScripts-RxHub, +1-917-414-5289, [email protected]

Web site: http://www.wellpointnextrx.com/http://www.surescriptsrxhub.com/

Zynx Health Clients Earn High Rankings in Study on Healthcare Quality

Zynx Health, the leader in evidence-based healthcare, announced that a number of its clients have earned high rankings in a recent study conducted by the Network for Regional Healthcare Improvement (NRHI), an organization that accelerates improvement in the financial and clinical value of healthcare delivery in the United States.

The study, published in The Joint Commission Journal on Quality and Patient Safety, aimed to examine how quality differs in the most commonly measured clinical areas for health systems. More than half of the 50 top-ranked health systems license either ZynxOrder(TM), a solution used to customize and update evidence-based order sets, or ZynxCare(TM), a solution which allows users to customize and maintain interdisciplinary plans of care and bring evidence-based knowledge to clinical teams at the point of decision making.

Zynx wishes to extend special congratulations to Alegent Health, a ZynxOrder and ZynxCare client that achieved the #1 ranking in this highly competitive group. The Omaha, Nebraska-based health system has been named among the “25 Top Connected Healthcare Facilities” by Health Imaging & IT magazine, and is considered one of the most technologically advanced health systems in the nation. Guided by its strategic plan, “The Quality Revolution,” Alegent Health has sought to improve its overall quality of care and enrich the patient experience, with Zynx evidence-based decision support as a key component of this initiative.

“Alegent Health’s #1 ranking in quality is proof of an enduring commitment to patient safety and the practice of evidence-based healthcare,” said David Rhew, MD, vice president of content and client services for Zynx. “Zynx Health is proud to be the content provider of evidence-based order sets and interdisciplinary plans of care for Alegent Health.”

“This outstanding achievement reflects a commitment to the highest standard of patient care in the industry from everyone at Alegent,” said Wayne Sensor, chief executive officer of Alegent Health. “Three years ago, we set out to revolutionize patient care by openly reporting our quality scores and costs, and by partnering with Zynx to integrate evidence-based care throughout our organization. As a result, we found that our quality scores soared and patients were placed at the center of all we do. These results make it clear that we are living by our commitment.”

About Zynx Health

Zynx Health, a subsidiary of Hearst Corporation, is the leading provider of evidence-based clinical decision support. Its team of physicians, nurses, and allied health professionals rigorously reviews the latest peer-reviewed literature to develop clinical summaries and distill evidence-based best practices that help improve the quality of patient care. More than 1,400 hospitals nationwide trust evidence-based decision support from Zynx Health to address regulatory initiatives, optimize pay-for-performance reimbursement, and measurably improve the quality and safety of patient care. For more information about Zynx Health, visit www.zynx.com or call 888-333-ZYNX (9969).

About Alegent Health

Alegent Health is the largest not-for-profit, faith-based healthcare system in Nebraska and southwestern Iowa with nine acute care hospitals, more than 100 sites of service, over 1,300 physicians on its medical staff and 9,000 employees. Alegent Health is making healthcare better with an exceptional commitment to quality and by providing patient-focused care for the body, mind, and spirit of every person. At Alegent Health, patients and their families find a continuum of care, from women’s and children’s services, primary care, wellness counseling, and senior care to cardiovascular services, orthopaedics, oncology, physical rehabilitation, and behavioral health. Alegent Health is sponsored by Catholic Health Initiatives and Immanuel Health Systems.

American Specialty Health Garners Top Healthcare Advertising Awards

SAN DIEGO, Aug. 20, 2008 (GLOBE NEWSWIRE) — American Specialty Health (ASH), a leading national health improvement organization, received six Healthcare Advertising Awards-two gold, two silver, and a bronze, plus a merit distinction-from Healthcare Marketing Report. The Healthcare Advertising Awards celebrated its 25th anniversary with a record number of entries, making it both the oldest and largest health care advertising awards competition.

A national panel of judges reviewed 4,400 advertising and marketing entries from various health care-related organizations. The entries were judged on creativity, quality, message effectiveness, consumer appeal, graphic design, and overall impact. Gold awards were given to 403 companies; 328 entries were awarded silver distinctions.

   *ASH won a gold award for its Redefine Senior Moment(tm) and Healthy    Aging is Hot(tm) posters, which were created to promote ASH's    Silver&Fit(r) healthy aging program. The posters feature colorful and    lively images of older adults participating in "age-defying" physical    activities such as sky-diving and surfing.   *Another gold award was given to ASH for its FitnessCoach(r) logo    design. FitnessCoach.com is an innovative health improvement program    that helps members take charge of their health through a variety of    online tools. The logo features an eye-catching orange and white    combination set upon a deep blue backdrop. In addition to the gold    award, FitnessCoach.com earned a merit distinction for its online Flash    classes, which teach members how to live healthier.    *ASH received two silver awards for its eXtremeQUIT(r) and    eXtremeLIVING(r) member education materials, created to give children    and teens-and their parents-the tools they need to quit smoking or live    healthier. With versions designed for children of different age levels,    the materials are accompanied by pocket-sized journals, incentive    brochures, and parent guidebooks.   *A bronze distinction was awarded to ASH for its colorful and vibrant    Health Plan Sales brochure. 

“To be recognized by such an esteemed publication as Healthcare Marketing Report-and to have our work acknowledged in such a large pool of worthy competitors-is a true honor,” said George DeVries, ASH CEO and chairman. “These awards only reinforce our commitment to producing creative, cutting-edge programs and materials for our members and clients.”

About American Specialty Health

American Specialty Health Incorporated (ASH), a leading health improvement organization, provides specialty benefit programs, fitness programs, health coaching and incentives, Internet solutions, and worksite wellness programs to health plans, insurance carriers, employer groups, and trust funds nationwide.

Based in San Diego, ASH has over 600 employees and covers more than 13.4 million members in specialty benefit, fitness, and coaching programs. For more information, visit ASHCompanies.com or call 800.848.3555.

This news release was distributed by GlobeNewswire, www.globenewswire.com

 CONTACT:  American Specialty Health           Debby Clark            800.848.3555            [email protected]           Tim Curns            619.578.2000            [email protected] 

Petrobras Inaugurates Pecem LNG Regasification Terminal

Integrated energy major Petrobras has inaugurated a liquefied natural gas regasification terminal at the Port of Pecem, in the Sao Goncalo do Amarante municipality of the Ceara state in Brazil.

It is reported that this is Brazil’s first liquefied natural gas (LNG) regasification terminal.

This terminal establishes Petrobras as a player in the international LNG market. Petrobras’s second terminal will be inaugurated later in 2008, in the Guanabara Bay in the Rio de Janeiro state of Brazil.

The Pecem terminal is capable of regasifying seven million cubic meters per day, equaling about half of the natural gas consumption destined to the thermal market nationwide.

The regasification terminal represents an addition of 11% to the natural gas supply in the Brazilian market, currently at 60 million cubic meters per day. The gas processed in Pecem will be used primarily by the Termoceara and Termofortaleza power plants in the Ceara state and the Jesus Soares Pereira power plant in the Rio Grande do Norte state.

Company Cars Are the Future

Assembly Health Minister Edwina Hart is presently involved in creating a more efficient and cost-effective health service and already she plans to abolish trusts established by her predecessor.

This is very commendable as cost-efficiency is paramount, especially as cancer patients in Wales are being refused certain treatments and life-prolonging drugs as the finance is not available and the extra life expectancy not deemed viable.

The unavailability of funds is invariably the result of waste and a lack of managerial control of budgets. One sure way of curtailing unnecessary expense would be to replace the company car park with pool cars based at strategic locations to be used as and when required.

I know that the company car scenario within the ambulance service, for example, has spiralled.

There could be huge benefits if Edwina Hart commissioned an inquiry into the issue of company cars within the health service, which, I am sure, would ultimately yield substantial savings that could be used for the benefit of patients.

John Lewis

Gower Road

Killay

Swansea

(c) 2008 South Wales Evening Post. Provided by ProQuest LLC. All rights Reserved.

Life and Death of Hawkmoor

Today it survives only as a name on a map, but in its time Hawkmoor Hospital at Bovey Tracey housed hundreds of patients.

It had two distinct lives, firstly as a chest hospital founded in 1913 to treat people with TB and then, as this awful disease became less common, as a hospital for those with mental disability.

Remote locations were often chosen as sanatoriums, the country air was cleaner than in smokey towns but there was probably also an element of not-in-my-backyard, such was the fear of infectious diseases like TB.

The buildings at Hawkmoor were extended in 1949 but with the advent of the NHS cases of TB declined.

In the 1970s its function switched to mental health and a very different congregation gathered each Sunday in the hospital chapel. In 1984 it accommodated over 100 patients many of whom had been living in instituition all their lives.

But a wind of change was blowing through the old-fashioned asylums. It was called “care in the community” and across the country the old residential mental hospitals began closing in their droves. Hawkmoor and its sister hospital at Starcross were among the first to be targeted.

By 1986, patient number were declining steeply and a closure date of December 1987 was set. When the last residents left for other instituitions or set out to begin life in the community, many for the first time, hundreds of jobs went with them.

Property prices were booming and the attractive hilltop site, within the Dartmoor National Park, was put on the market. Initial plans to convert part of the hospital for flats were dropped and instead the health authority went for wholesale demolition, with the exception of the wood-beamed 1913 chapel.

Before the bull-dozers moved in however, there was to be one last group of residents in the old hospital. New Age travellers found it and declaring themselves conservation protesters (they said there was important wildlife on the site) occupied a wing with their children. Only after a protracted legal battle did they leave.

Today Hawkmoor is gone and instead expensive detached homes occupy the site which was once a sanctuary for many thousands of patients. But at least the name survives in Hawkmoor Park, the name of the new development.

(c) 2008 Herald Express (Torquay UK). Provided by ProQuest LLC. All rights Reserved.

Family and Friends CPR to Be Held

The Jackson County Regional Health Center and the American Heart Association are teaming up for a potentially life-saving event.

Teaching the basic skills of CPR, the organizations are sponsoring Family and Friends CPR at the health center, 700 W. Grove St. in Maquoketa at 5:30 p.m. Thursday, Aug. 21, in the large conference room.

Two 90-minute classes, which will cover CPR skills for adults, children and infant victims, will be offered and are open to the public.

For more information, contact the health center at 563-652-2474, ext. 4161.

(c) 2008 Telegraph – Herald (Dubuque). Provided by ProQuest LLC. All rights Reserved.

Stem Cells for Liver Repair?

By Risha Chitlangia

New Delhi: The paediatric surgery department at All India Institute of Medical Sciences (AIIMS) is conducting a pilot study to see the effects of stem cell in treating biliary atresia, which results in liver cirrhosis. Biliary atresia is a rare condition in which the common bile duct between the liver and the small intestine is blocked or absent. The department started the pilot project after getting encouraging results from initial trials which have been going on for three years.

“Liver transplant is the only solution to liver cirrhosis caused due to biliary atresia today. But in infants there is little success and not many families are able to get a donor,” said Dr D K Gupta, head of the department, paediatric surgery , AIIMS.

So far the department has given 15 infants with cirrhotic liver stem cell treatment . Of them, eight have survived. “We are not saying that it is a definite cure for biliary atresia, as a lot of study and research is still required to come to that conclusion. These are medically written off cases and slight improvement with the use of stem cells gives us hope that it could be developed,” said Dr Gupta.

risha.chitlangia@timesgroup .com

(c) 2008 The Times of India. Provided by ProQuest LLC. All rights Reserved.

Vital Research is the Poor Relation

Everybody has heard of Cancer Research, and everybody has also heard of the British Heart Foundation: but stop 10 people in the street and ask them what they know about the British Lung Foundation, and one would be lucky to find one with any recognition of its existence. I know; I’ve tried it: yet this charity has been running for over 20 years. The disheartening statistics are that, on average, one member of every family has a lung problem, with resultant breathing problems, illnesses from work and premature death. Lung disease is not funny.

As a charity, the British Heart Foundation last year raised over pounds100million. The British Lung Foundation (BLF) in that year raised just under pounds5million, and this 20-1 disparity in the amount of recognition for each certainly needs addressing. After the scourge of cancer, the heart and lungs are the things that keep us alive, and problems with either lead to heartbreaking (and lung- breaking) consequences. There are over 40 separately- identified lung diseases, and much more research into all aspects of the treatment of each is urgently needed.

With our government too wrapped up in spending our taxes on its own priorities to support much in the way of lung research, it seems that charity is the only way solutions to the plight of people with breathing difficulties can be addressed. The BLF has set up over 200 local support groups to raise money for research, several in the South West; as well as organising events, the one in Plymouth with which I am associated has a monthly meeting at 1.30pm on the first Tuesday of every month at Tothill Community Centre, which anyone with an interest in the subject is more than welcome to attend (for tea and biscuits, talks from experts in various fields, and general discussion in a relaxed and friendly atmosphere).

And to those rich enough, can I say that if you’re wondering which of the many you could nominate for your next charity donation, I have a suggestion.

(c) 2008 Plymouth Evening Herald, The. Provided by ProQuest LLC. All rights Reserved.

‘Report Says Fluoride’s in No Way Beneficial’

The Government’s own commissioned report decided that there is absolutely no evidence that fluoride benefits teeth and that there could actually be a “disbenefit”.

Its researchers found that about half of all children in fluoridated areas have dental and sometimes skeletal fluorosis, much of it “worrying.” Future long term effects include thyroid deficiency and cancer.

Could Kate Taylor-Weetman write in and explain why, since fluoride has been officially declared to be useless, she finds it necessary to add a substance in the same poison category as paraquat to our tap water?

At its last meeting in November the Nuffield Council on Bio- Ethics considered the addition of fluoride to the water supply unethical.

Professor J. Montgomery of Southampton University said that if health authorities wish to impose fluoridation on the public, then they have a duty and a moral obligation to give full information about its dangers. Could Kate Taylor-Weetman tell us when these disclosures will be made?

KATE BOULTON Biddulph

(c) 2008 Sentinel, The (Stoke-on-Trent UK). Provided by ProQuest LLC. All rights Reserved.

Check the Sugar in Toothpaste

With reference to the article Mass medication back with fluoride (The Sentinel, August 14).

You then ask the question should fluoride be added to the water? Of course the answer is absolutely not. Fluoride is a highly toxic substance and is not needed at all in our water toothpaste or anything else we might use to clean our teeth or digest.

What is actually needed is better control of our manufactured food and not allowing our children to stuff their faces with bag after bag of sweets, cakes or sweet fizzy drinks.

I have very good teeth, not because I have used fluoride, but because I wasn’t allowed too many sweet and sticky things while growing up.

I was allowed some sweets, but I had to brush my teeth with non- fluoridated toothpaste afterwards.

This is taking away our right to have clean unadulterated water.

You can get fluoridated toothpaste you can use, but personally I don’t touch it at all. I use natural toothpaste, not mass-produced products that are advertised on TV.

Also check the toothpaste you are using hasn’t got a lot of sugar added to make it more palatable.

I believe the answer is to make sure that pre-packed products don’t have too much sugar in them.

Give children boundaries on how much sweet stuff they can eat and drink and stick to it, and make sure they clean their teeth after eating sweets and after every meal or at least two times a day, especially before they go to bed.

Also, can someone answer me a simple question? Why are dentists allegedly supporting this? Surely they are shooting themselves in the foot by backing this. If we have perfect, strong teeth, we won’t need them anymore, will we?

ANN BEIRNE Wolstanton

(c) 2008 Sentinel, The (Stoke-on-Trent UK). Provided by ProQuest LLC. All rights Reserved.

Glenelg Druggist Fights Store Closures

By Brendan Kearney

Facing criminal charges for mislabeling prescription drugs and the de-licensing of her two Baltimore locations by Medicine Shoppe International Inc., a Glenelg pharmacist is fighting to save her business and her reputation.

Pamela E. Arrey sued the Missouri-based chain on Monday and won a temporary restraining order that prevents it from terminating her license agreements, at least for the next 10 days, according to Joseph M. Kum, one of her attorneys.

Federal and state inspections last month at Arrey’s Liberty and Reisterstown road locations found falsified expiration dates on drug containers, misspelled drug names and other label alterations, according to the affidavit of a Food and Drug Administration special agent that accompanied Arrey’s arrest warrant.

The mislabeled drugs included those to treat epilepsy and breast cancer, according to the affidavit.

Arrey, 47, was charged with multiple counts of prescription drug fraud on July 28.

On Saturday, she received a letter from a Medicine Shoppe attorney terminating her license agreements, according to her lawsuit filed in U.S. District Court in Baltimore.

Her suit accuses Medicine Shoppe International of “spreading injurious falsehood to tarnish Plaintiff’s business reputation.”

Kum, of Amity, Kum & Suleman P.A. in Greenbelt, said the impounded drugs were to be shipped either to Cameroon or to Tampa- based PharmaLink Inc., a drug disposal company.

“None of the drugs were ever on the shelves,” Kum said. “Those drugs were not meant for sale here, and none of them were sold.”

A state inspector visited the Liberty Road Medicine Shoppe on July 8 and reported 11 cardboard drums of “suspicious bulk prescription drugs” to Matthew R. Rosenberg, the FDA special agent who swore out the affidavit. The state inspector, Chandra Mouli, found drugs in relabeled stock bottles were identical to those in the drums, according to the affidavit.

Rosenberg found similar issues when he inspected what had been impounded on July 17. The Maryland Board of Pharmacy inspected the Reisterstown Road pharmacy on July 21 and found stock bottles there that had similarly altered expiration dates, according to Rosenberg’s affidavit.

According to its Web site, Medicine Shoppe International has 10 pharmacies in the Baltimore area, including Arrey’s.

In statements to the press, the St. Louis-based company said it “learned that two of our Baltimore-area pharmacies …were recently found by the [FDA] to have sold expired medications. … [W]e do not condone these type of infractions by our licensed pharmacies.”

Beyond e-mailing the same statement, a spokeswoman for the company declined to comment on Monday afternoon.

Destined for Cameroon

Kum said the drugs at issue were in a back room and had come from the Catholic Medical Mission Board Inc. intended for e-Meditech, a Burtonsville-based aid organization that partners with programs in Cameroon, Kenya, Nigeria and Uganda. Kum said those drugs, in drums at the Liberty Road location, were not expired.

According to the affidavit, Arrey makes routine trips to Cameroon, where she owns a pharmacy and clothing store. As part of the criminal proceeding, Arrey has forfeited her passport and put up the deeds to two homes. She is prohibited from working in a pharmacy or leaving the state.

Other drugs in bags were expired or near-expired and were meant for disposal, Kum said, noting Arrey has a bill of lading as proof.

Kum said the July 8 inspection was especially thorough, leading him to believe that someone had tipped off the state agency.

Rosenberg’s affidavit notes Arrey’s stores have been cited “regularly” by the Maryland Board of Pharmacy and the Division of Drug Control for “repeated” violation of state pharmacy laws since 2004.

Kum calls that claim “false,” saying he successfully defended Arrey against one citation four years ago.

Despite the turmoil, Kum said Arrey’s two pharmacies remain open. Her suit against Medicine Shoppe requests injunctive relief to prevent interruption in her 16-year-old business. No preliminary injunction hearing has been scheduled, Kum said, adding the case might be transferred to Missouri.

Originally published by Brendan Kearney.

(c) 2008 The Daily Record (Baltimore). Provided by ProQuest LLC. All rights Reserved.

Baby Found in Gym Bag on Street

Police in Hempstead, N.Y., searched Tuesday for the mother of a newborn girl found in a gym bag.

Lt. Vincent Montera said police got a call at about 11 p.m. Monday giving the baby’s location, Newsday reported. Officers who responded found the baby in a black Polo gym bag.

The baby was reported to be in good condition at a hospital.

Montera said he did not know if the caller Monday night was male or female.

Hempstead is on Long Island, a few miles east of the New York City line.

Research Ties Skin Creams to Cancer

HACKENSACK, N.J. – Moisturizers may speed skin cancer in reformed sunbathers, even years after giving up on tanning, according to a Rutgers University study of mice.

Four different brands of moisturizing creams caused tumors to form faster and larger in hairless mice that had been pre-treated with ultraviolet radiation, the Rutgers researchers reported Thursday in the Journal of Investigative Dermatology.

“We don’t know what happens in humans,” said Alan Conney, who headed the study. “But this is a red light saying there should be some epidemiological study in human populations.”

Manufacturers of the products – Eucerin Original Moisturizing Creme, Vanicream, Dermabase and Dermovan, all chosen randomly for the study – refuted the findings Thursday.

Conney said it is not known which ingredients act as the mechanism that could promote skin cancer. “There was no common ingredient” in the moisturizers that was suspect, he said. “It has to involve the combination of ingredients.”

– McClatchy Newspapers

(c) 2008 Bismarck Tribune. Provided by ProQuest LLC. All rights Reserved.

ACOEM Chronic Pain Guidelines Now Available Online

WESTMINSTER, Colo., Aug. 19 /PRNewswire/ — The American College of Occupational and Environmental Medicine (ACOEM) today published new medical treatment guidelines for providing care to workers with chronic pain. The new guidelines, which represent the latest chapter in ACOEM’s comprehensive publication Occupational Medicine Practice Guidelines, are available online now; in September a print version will be available.

More than 200 recommendations for chronic pain are outlined in the new evidence-based guidelines, which were developed by a multi-disciplinary panel of national experts and were reviewed by representatives of leading medical and health organizations. The recommendations focus on diagnostic and other testing and treatments for several chronic pain conditions, including: complex regional pain syndrome (CRPS), neuropathic pain, trigger points/myofascial pain, chronic persistent pain, fibromyalgia and chronic low back pain.

An extensive volume of literature was utilized to develop the recommendations, which feature more than 1,500 references, including 546 randomized controlled trials.

“These guidelines were developed using ACOEM’s published methodology, which incorporates the highest scientific standards for reviewing evidence-based literature, ensuring the most rigorous, reproducible, and transparent occupational health guidelines available,” said Editor-in-Chief Kurt T. Hegmann, MD, MPH. “Literally thousands of hours of review of the available scientific literature went into this process, yielding what we consider state-of-the-art medical guidelines.”

Other highlights of the new chronic pain guidelines include:

— An in-depth review of over 20 medications (prescription, over-the-counter, complementary and alternative) used to treat patients with chronic pain, including an extensive appendix on guidance for the use of opioids.

— Detailed recommendations regarding the use of appliances (e.g., magnets), skilled allied-health provided medical therapies (e.g., acupuncture, manipulation/mobilization, myofascial release), electrical therapies (e.g., PENS, TENS).

— Uses and limitations of injection therapies (e.g., diagnostic and therapeutic facet joint injections, trigger/tender point injections, botulinum injections, intrathecal drugs).

— A discussion of spinal cord stimulation for CRPS and other painful conditions.

— A detailed review of psychological services (e.g., evaluation and behavior therapy) and rehabilitation for delayed recovery, including biofeedback, work conditioning/work hardening/early intervention programs, and interdisciplinary pain rehabilitation programs.

— A focus on functional restoration, including an active exercise program and behavioral program.

In addition to being available electronically, the new chronic pain guidelines will also be available in a new print edition of the Occupational Medicine Practice Guidelines 2nd Edition, 2008 Revision, which is currently in production. Orders are being accepted now for delivery in September of this comprehensive volume, which includes guidelines on a variety of musculoskeletal conditions. Individual chapters from the print publication are also available at ACOEM’s website.

ACOEM’s online treatment guidelines are exclusively distributed by Reed Group. For more information, or to order UMK Professional or the ACOEM Guidelines Electronic version, visit http://www.reedgroup.com/ or call a product consultant at 866.889.4449.

About Reed Group:

Dr. Presley Reed founded Reed Group in 1981 to address workplace productivity and employee absenteeism issues in the corporate environment. Reed Group maintains four key lines of business: Guidelines, Service, Data Analytics, and Education. In addition to providing integrated clinical case management service for non-occupational and occupational leaves, Family Medical Leave Act (FMLA) and other leave of absence administrative services to employers, Reed Group publishes the industry-standard disability duration guidelines, The Medical Disability Advisor (textbook, Windows software, and Internet and data integration versions), now in its Fifth Edition. For more information, call 866.889.4449, or visit http://www.reedgroup.com/.

About ACOEM

The American College of Occupational and Environmental Medicine (ACOEM) represents more than 5,000 physicians specializing in occupational and environmental medicine. Founded in 1916, ACOEM is the nation’s largest medical society dedicated to promoting the health of workers through preventive medicine, clinical care, disability management, research, and education. For more information, visit http://www.acoem.org/.

Reed Group

CONTACT: Matt McLaughlin, Marketing Manager of Reed Group,+1-303-407-0663, [email protected]

Web site: http://www.reedgroup.com/http://www.acoem.org/

Competing With the Clock

By White, Karen

Make competition rehearsals count with strategies to best utilize your-and students’-time. Students of D’Valda and Sirico’s Dance and Music Centre perform She Dances at competition.

The hands on the clock fly around, the next competition looms, yet the numbers need more polishing. Team kids already spend endless hours at the studio in regular classes. How do you fit in enough rehearsal time?

The secret isn’t to schedule last-minute rehearsals or to eat up dancers’ entire weekends, but to have a well-thought out plan for the whole year that incorporates competition group time into your weekly class schedule. Here are some tips to help you do just that.

Take the pressure off weekends.

That’s what Stina Smith of Jersey Cape Dance and Gymnastics Academy in Cape May, New Jersey, did this year. Since many of her school’s 34 team members already take technique classes between three and six days a week-even the 6-year-olds-she used to teach team choreography in marathon 9-to-5 sessions on Saturdays. When that wasn’t getting the job done, Smith began bringing in soloists on Sundays. She quickly realized that enough was enough.

“Before we demanded any more of the kids, this year we tried something different. We added a choreography class every week,” she says. Each of the studio’s four teams has its own class on a weeknight, during which members learn and perfect their competition routines, greatly reducing the Saturday commitments. Smith also gave students every other Saturday off at the beginning of the season. “So far, it seems to be working out well,” she says.

Adding a choreography class to the weekly schedule can also prevent rehearsals from encroaching on technique classes. This is the first year Smith hasn’t felt pressured to take time out of class to focus on her competition team-a practice that was unfair to her recreational dancers. “Our recreational students would be sitting around, because they didn’t choose to compete,” she says, “but I felt I had to put that time into the team.”

Limit individual time commitments.

Using regular class time for team rehearsals is a “disaster,” says 21-year veteran studio owner Steve Sirico of D’Valda and Sirico’s Dance and Music Centre in Fairfield, Connecticut. “Parents will have a fit over that.” Sirico’s performance group members attend specific weekly classes to learn competition material, plus a Saturday practice once a month. Rehearsal time varies for each dancer. Auditions are held at the start of the season, and dancers are chosen for numbers based on set skills. A preteen tapper, for example, might be in only one tap number, while a more advanced dancer appears in tap, lyrical, jazz and hip-hop routines. This set- up allows for greater flexibility.

“We try and get the best out of each group,” Sirico says. “It doesn’t overwhelm them and they can compete if they dance for as little as five hours a week, between rehearsals and technique classes.”

The system is a result of “banging our heads against the wall trying to get kids to commit” to the traditional team approach, he says. This year, the performance group numbers 70 dancers, 50 of whom are handling multiple routines. Truly serious dancers can strive for the more elite 25-member studio company, which requires a higher commitment of technique class and rehearsal time.

“The parents love it. Before, the number of hours required would scare them away,” Sirico says. “This gives more kids a chance to be part of the team. If they desire more, they can take those additional classes and work on that particular technique.”

Save time with advance planning.

At Retter’s Academy of Dance in Agoura Hills, California, many parents juggle their kids’ schedules along with their own jobs and family lives. This realization is what prompted Co-owner and Co- director Linda Bernabei-Retter to organize a team calendar that lists all classes, rehearsals and competition dates at the beginning of the season. Sticking to it has become imperative, Bernabei- Retter says.

“It’s all on the calendar, so they can see if they can commit,” she says. “About 10 years ago we realized we were not meeting the needs of these parents, and for us, this has been the way to go.”

The 53 dancers in her mini, junior, teen and senior teams all attend company choreography classes on Thursdays. In October and November, when dances are being set, the team also rehearses on Sundays from 11 am to 2:30 pm. As choreography is mastered, fewer Sundays are required.

Make the most of rehearsals and classes.

Good time management means getting the maximum from dancers in rehearsal and class. If a dancer has a test the next day and can’t concentrate, Sirico will allow a day off from rehearsal with the understanding that the material has to be made up in a half-hour private lesson.

“We try to give them a balance. If you come in and you’re fried, tired and distracted, you’re no good to us. Stay home, do your homework,” he says. “Then come back refreshed and ready to go.”

Bernabei-Retter’s husband and business partner, Darryl, grew up spending endless days and nights at his mother’s dance studio. Neither of them wants that for their own daughter, or their students. That’s why they are careful to start and end rehearsals on time, and keep the dancers dancing fully. Every minute is put to good use, and the dancers themselves know their time will not be wasted. Understudies are set for all pieces, allowing for rehearsals to continue productively if a dancer is injured or absent. Because time is wasted when material must be repeated for absent dancers, rehearsals are mandatory when choreography is being taught.

In addition, all of the Retters’ teachers must arrive for team rehearsals with choreography worked out in advance. “With limited time, those days when we could set choreography on the students are gone. For me, it can take up to 17 hours to pre-produce a number before the kids see any of it,” she says. “It’s difficult, but I insist.”

Remember that time flies when you’re having fun!

With so much repetition required for performance perfection, the fun of competing often gets lost. To keep the experience fresh and exciting, Sirico’s group members attend only two or three events a season. Performance group members hone their routines in front of the recreational students-who, in turn, are happy to show off their own recital routines.

To mix things up, Bernabei-Retter invites master teachers to teach team classes. Sometimes she might run a mock audition. When the tension is thick, she’ll remind the dancers to “check your ego at the door and keep your sense of humor.”

If a rehearsal is lagging, Jersey Cape team dancers will “circle up” and do a motivational exercise, such as saying one nice thing about each other. On “cleanup days,” Smith and her faculty play “good cop, bad cop,” just to make sure the dancers hear some praise along with the technical comments. She also designates one rehearsal as the annual “trophy smash,” where dancers work out their frustrations and anxieties by beating on last year’s trophies with large rubber hammers. “After all, the team is not about trophies, but about reaching personal goals,” Smith explains.

All teachers should watch for the warning signs of burnout: exhaustion, crankiness and zoning out. Usually the culprit isn’t dance alone, but a mix of schoolwork and extracurricular activities- such as school plays, cheerleading, etc.-weighing heavily on a student. Then, it’s time to sit down with the dancer and his or her parents for a chat about commitment and making choices.

In the end, there’s no one surefire way to beat the clock. “We could always hold another rehearsal, but at some point you have to let it go,” Bernabei-Retter says. “There are other lessons to be learned, such as how to work in a more focused manner in the time the company does have.”

“We could always hold another rehearsal, but at some point you have to let it go.”

-Linda Bernabei-Retter

Karen White is a freelance journalist and longtime dance instructor in Taunton, MA.

Copyright Lifestyle Ventures Aug 2008

(c) 2008 Dance Teacher. Provided by ProQuest LLC. All rights Reserved.

The M2-F1: Forefather to the Space Shuttle

The planned retirement of the space shuttle fleet in 2010 will bring to a close an era that opened in the Antelope Valley nearly a half century ago.

The vehicle which began that era ““ the M2-F1 ““ was an unlikely forefather to the shuttle. The world’s first manned lifting body, the M2-F1 was made of wood, had an internal framework of steel tubes, looked like a bathtub sitting on a tricycle, and had no wings.

Conceived by NASA engineers at the Ames Research Center, the lifting body was intended as an alternative to a capsule spacecraft, which returned to Earth dangling under a parachute. A lifting body was not a conventional winged aircraft, but rather, used air flowing over its fuselage to generate lift. This design allowed it to renter the atmosphere and land on a runway like a conventional airplane.

The idea of an aircraft without wings met with skepticism among engineers. R. Dale Reed of the NASA Flight Research Center (now the Dryden Flight Research Center) was the exception. Reed was excited about the concept, and began testing a series of small balsa wood and tissue-paper lifting bodies which he flew down the hallways of the center’s main office building and off its roof.

Reed was successful in raising interest in the concept, and center director Paul Bikle approved discretionary funding to construct a “homebuilt” lifting body called the M2-F1 (for “Manned 2 Flight 1).

Noted sailplane builder Gus Briegleb, who built wooden high-performance sailplanes at his facility at the El Mirage Airport some 40 miles from the center, was engaged to build the fuselage. The internal framework was built in a curtained-off section of Briegleb’s hangar with a sign reading “Wright’s Bicycle Shop.” Using volunteer help from center personnel, Reed kept the cost of building the M2-F1 to about $30,000.

Because the M2-F1 was unpowered, a tow vehicle was required. Walter “Whitey” Whiteside, a hot-rod enthusiast who worked at the center, was sent to purchase a new 1963 Pontiac convertible. Following modification at two race shops, the car was capable of reaching 110 miles per hour with the M2-F1 in tow.

The first car tow attempts were made on March 1, 1963, with NASA research pilot Milton O. “Milt” Thompson in the cockpit. The M2-F1 vehicle bounced back and forth on its main landing gear, and was unable to lift off the lakebed surface. Following the poor results, the M2-F1 was taken to the Ames Research Center outside San Francisco for wind tunnel testing, which lasted until March 15. The vehicle’s control system was modified based on the data.

The second attempt to fly came on April 5, 1963. Thompson was able to lift off and remain airborne for longer periods of time while the tow car roared across the lakebed. After several flights, he was able to remain aloft for the whole four miles of the run. During the spring and summer, Thompson made more car tow flights, to higher speeds and altitudes.

The first M2-F1 free flight came on August 16, 1963. A C-47 towed the M2-F1 to an altitude of about 5,200 feet above the lakebed. Thompson released the towline and began a steep descent. The flight lasted under two minutes, with an average descent rate of 4,000 feet per minute. The M2-F1 handled well during the brief flight.

Thompson made several more flights during the summer and fall. By the time the M2-F1 was retired on August 18, 1966, it had made 77 air tow flights and about 400 car tows.

By this time, the first “heavyweight” lifting body, the M2-F2, had begun flights, launched from the NB-52 mothership. The M2-F2’s design was similar to the M2-F1, and had similar flight characteristics during its unpowered phase. This and the subsequent manned lifting bodies, the HL-10, X-24A, M2-F3, and the X-24B, set the stage for construction of the space shuttles.

Although in the end the lifting body design was rejected for the shuttle, the lifting bodies provided extensive data on the aerodynamics and controllability of a low lift-over-drag unpowered vehicle that was directly applicable to the design of the shuttles.

The M2-F1 was restored in the mid-1990s, and returned to NASA Dryden in August 1997 where it remains on display today.

On the Net:

www.nasa.gov

Study Suggests Polygamy May Lead To A Longer Life

New research suggests that men from polygamous cultures outlive those from monogamous ones.

Virpi Lummaa, an ecologist at the University of Sheffield, suggested that after accounting for socioeconomic differences, men aged over 60 from 140 countries that practice polygamy to varying degrees lived on average 12% longer than men from 49 mostly monogamous nations.

The research looks to solve the long-standing puzzle of life expectancy in human biology.

A phenomenon called the grandmother effect seeks to explain why women are able to live so long after the menopause””unlike nearly all other animals.

Lummaa says for every 10 years a woman survives past the menopause, she gains two additional grandchildren. It seems that doting on and spoiling grandchildren aids their survival, as well as furthering some of their grandmother’s genes.

By contrast, men can reproduce well into their 60s and even 70s and 80s, leading most researchers to assume this explained their longevity.

However, Lummaa and colleague Andy Russell wondered whether other factors explained the long lifespan of men, such as a grandfather effect.

The team tested this possibility by analyzing church-gathered records for 25,000 Finns from the 18th and 19th centuries, when people tended to move little, no one practiced contraception and the Lutheran Church enforced monogamy.

During this era, only widowed men were allowed to remarry, and if they had children with their new wife, they fathered more kids, on average, than men who married once.

“Ultimately, remarried men don’t end up with any more grandchildren. If anything the presence of a grandfather was associated with decreased survival of grandchildren,” Lummaa said.

“Perhaps the children of the first mother lose out on food and resources that go to the second mother’s kids. It’s kind of the Cinderella effect,” Lummaa added.

A finding supported by previous research showed even fathers with only one wife provided no benefit to their grandchildren.

After ruling out the grandfather effect, Lummaa and Russell next wondered whether the constraints of human physiology explain male longevity.

They suggested that male longevity might be a consequence of biological selection for long-lived women.

The researchers then compared the lifespan of men from polygamous countries with those from monogamous nations.

The team then scored 189 countries on a monogamy scale of one to four – totally monogamous to mostly polygamous, taking into account a country’s gross domestic product and average income to minimize the effect of better nutrition and healthcare in monogamous Western nations.

“Our monogamy score is a crude first stab, and we’re working to find multiple ways to assess marriage patterns,” Lummaa said. She also added that the conclusions could evaporate under further analysis.

The study suggests that if female survival is the main explanation for male longevity, then monogamous and polygamous men would live for about the same length of time.

However, it seems that fathering more kids with more wives leads to increased male longevity. Men, then, live long because they’re fertile well into their grey years.

This could be both a social and genetic explanation.

Men who continue fathering kids into their 60s and 70s could take better care for their bodies because they have mouths to feed. But evolutionary forces acting over thousands of years could also select for longer-lived men in polygamous cultures.

Chris Wilson, an evolutionary anthropologist at Cornell University in Ithaca, New York, who attended the talk, said the new study is a valid hypothesis and a good prediction.

But he believes the care and attention of several wives who depend on the social status of their ageing husband could explain everything.

“It doesn’t surprise me that men in those societies live longer than men in monogamous societies, where they become widowed and have nobody to care for them.”

On the Net:

ModernMed Announces Partnership With Dr. Neil J. Sapin, M.D.

GLENDALE, Ariz., Aug. 19 /PRNewswire/ — ModernMed, http://www.modernmed.com/, announced its partnership with Dr. Neil J. Sapin of Arrowhead Internal Medicine Specialists, http://www.modernmed.com/Sapin, to provide patients with primary care focused on prevention and aging well. Enhanced service offerings include same day or next day appointments guaranteed, an annual comprehensive wellness exam, direct access to Dr. Sapin and personalized health planning.

“ModernMed has the power to change the landscape of primary care,” said Jami Doucette, M.D., president and CEO of ModernMed. “By understanding and responding to the needs of physicians and patients in a way that is unique to the health care industry, ModernMed is ideally qualified to help build the relationships that will create the highest satisfaction of those who choose this extraordinary form of primary care delivery. Dr. Sapin has that desire to take primary care to the next level which makes our partnership a winning combination.”

Arrowhead Internal Medicine Specialists, a ModernMed practice, http://www.modernmed.com/Sapin, is designed to decrease severe illnesses and hospitalizations as well as guide the patient to their personal best level of health. While traditional primary care practices often have over 2,500 patients, which does not allow for much of a relationship with the physician, Dr. Sapin’s ModernMed practice will have only 500 patients. Having fewer patients will enable Dr. Sapin to provide extended office visits, test result consultations and secure on-line access for patients to their electronic medical records.

“I chose to affiliate with ModernMed because they promote total wellness for the patient which enables me to practice medicine the way I have always envisioned,” says Dr. Neil J. Sapin. Dr. Sapin is a Board Certified physician in Internal Medicine and has practiced for over 30 years in Glendale, Arizona.

About ModernMed

ModernMed, http://www.modernmed.com/, is a forward-thinking health care service firm focused on creating a new primary care paradigm that creates a better health care experience for patients, physicians, and corporations. ModernMed creates, implements, and maintains modern primary care practice environments across the country that provides high-quality, patient-centered atmospheres unlike any traditional practice setting. The ModernMed headquarters is in Scottsdale, Arizona.

ModernMed

CONTACT: Eve Schremp, Senior Vice President of ModernMed,+1-480-502-6777, [email protected]

Web site: http://www.modernmed.com/http://www.modernmed.com/Sapin

Sturgeon Opens Alcohol and Drug Addiction Centre in Glasgow

By STEWART PATERSON

A NEW centre for treating patients with alcohol and drug addiction was officially opened by Health Secretary Nicola Sturgeon yesterday .

The Kershaw Unit at Gartnavel Royal Hospital in Glasgow will co- ordinate services under one roof. Patients at the day unit receive detoxification, medication, therapy and help with returning to normal life once rehabilitated.

The service offers tailored support for patients whose drug or alcohol addictions require more extensive care than can be provided by community addiction teams, but who do not need the intense care provided by inpatient specialist services.

Ms Sturgeon said: “It is a fantastic facility. It is exactly the right environment for the services provided here. ” Patients attend daily for a range of treatments and opportunities to learn skills.

Joe Kelly, 51, has been receiving treatment for alcohol addiction for 10 years. He said: “This is much more modern than the other place and we are able to do more things. I come here and work in the garden every day and take my medication to keep me off the drink.”

Fellow patient Tam Kearns, 59, has been struggling with alcoholism for the past 15 years. He said: ” I am on the medication programme. It doesn’t work for everyone, but it helps me. Without this place I would be lying drunk somewhere.”

Iain Smith, consultant psychiatrist at Gartnavel Royal Hospital, said: “This unit brings together services. We can offer detoxification and then look at ways of keeping people off alcohol and drugs.

“We are on-site at the hospital and have access to seven beds in the main hospital for people experiencing severe difficulties who need admission.”

Originally published by Newsquest Media Group.

(c) 2008 Herald, The; Glasgow (UK). Provided by ProQuest LLC. All rights Reserved.

Golden Gate Pharmacy Implements digiMedical Digital Prescription Software

digiMedical Solutions, a developer of next generation digital medical technology, has announced that Golden Gate Pharmacy has implemented its digital prescription handling software to manage and fulfill prescriptions accurately and in line with HIPAA and DEA requirements.

According to digiMedical, its digital prescription software suite protects the pharmacist from errors caused by difficult-to-read handwritten prescriptions and the risk to the pharmacist of illegally duplicated prescriptions and fraudulent prescriptions. The digital prescriptions are routed directly and securely from the physician’s office or clinic to the pharmacy. The digital pack of information also contains pertinent patient information, allowing the pharmacy to pre-fill the prescription prior to the patient’s arrival at the pharmacy.

Additionally, digiMedical manages prescription refills for physicians’ offices and clinics through the company’s digiReauth software and call center services. The suite of software includes digiRX, digiRxStream, digiReauth, digiRxComp, and digiAccounting.

Keane Wins Multi-Year Contract From Johns Hopkins Hospital

Keane, a global IT services firm, has won a multi-year contract from The Johns Hopkins Hospital. Under the contract, Keane will deploy a front-end admission discharge and transfer solution and upgrade the hospital’s existing back-end billing solution to Keane’s new browser-based EZ-Access Patcom solution.

Keane claims that the front-end admission discharge and transfer solution (ADT) System, also browser-based, will take just over one year to fully deploy. The system is expected to streamline the hospital’s patient registration system from the point of admission through the discharge or transfer of the patient and will interface with over 200 systems within The Johns Hopkins Hospital. This includes the collection and management of critical patient data to improve patient safety and quality of care, as well as billing and insurance information, to streamline billing processes on the back-end.

According to Keane, upgrading the back-end billing system to Keane’s EZ-Access Patcom will give Johns Hopkins additional insight and functionality into patient billing, enhance the revenue cycle process and improve staff productivity, generating improved ROI for the hospital.

Walt Kaczor, senior vice president of healthcare solutions division at Keane, said: “The Johns Hopkins Hospital is a long-time client of Keane, and we’re delighted that they have selected us to implement a full admission, discharge and transfer solution, which is one of the most visible technology components in a hospital. We believe this project is a testament to the quality of our solutions and our ability to develop long-term client relationships.”

Bayhealth Medical Center and University of Pennsylvania Health System Sign Clinical Affiliation Agreement

Bayhealth Medical Center and the University of Pennsylvania Health System (UPHS) today announced that they have entered into an affiliation agreement to provide expanded cancer diagnosis, treatment, research and education to Delaware residents. Bayhealth Medical Center is the first healthcare facility in Delaware to become a member of the University of Pennsylvania Cancer Network.

The cancer affiliation with Bayhealth is UPHS’s first in Delaware and represents the further expansion of Penn’s clinical expertise in advanced cancer care among superior health-care facilities throughout the region. The relationship also brings university-level expertise in cancer care to Bayhealth and the first affiliation with an NCI-designated comprehensive cancer center to Delaware.

The University of Pennsylvania Cancer Network encompasses a select group of community hospitals throughout New Jersey, Pennsylvania and now Delaware. The network hospitals provide cancer care in their communities in collaboration with the Abramson Cancer Center of the University of Pennsylvania – one of the nation’s first NCI-designated Comprehensive Cancer Centers. The affiliation will provide Bayhealth’s cancer patients with direct access to the latest medical research and clinical trials close to home in a community hospital setting.

Through membership in Penn’s Cancer Network, Bayhealth patients will have access to a full continuum of specialty and subspecialty care and resources available via the Abramson Cancer Center – including standard and innovative preventative, diagnostic, and treatment services (including medial oncology, surgery, radiation oncology and integrated care/medicine), as well as programs in research and education for the benefit of cancer patients and their families. All participants in the University of Pennsylvania Cancer Network share a commitment to excellence in patient care and cancer research, as well as improvement in the health and well being of their communities.

Bayhealth’s membership in Penn’s Cancer Network comes close on the heels of the establishment of the Bayhealth Cancer Institute, which formalized Bayhealth’s longstanding commitment to provide premier cancer treatment, clinical research, education and prevention to Delawareans.

“Our partnership with Penn will provide our patients with the most comprehensive cancer care available today,” said Bayhealth President/CEO Dennis E. Klima. “We look forward to working with Penn specialists to develop additional mutually supportive programs that will further benefit our patients throughout Delaware.”

“The establishment of the Bayhealth Cancer Institute and now our partnership with Penn will provide Delawareans with superior programs and services in cancer care,” said Rishi Sawhney, MD, who leads the Institute. “Our collaboration with Penn’s dynamic team of physicians and researchers will further enhance our ability to apply clinical advances in cancer research to patient care, providing them with access to the most advanced treatments and promising new therapies.”

“We are privileged to join the Bayhealth Cancer Institute to implement this clinical affiliation in cancer medicine so that Bayhealth may continue its rich tradition of providing high-quality care to the communities it serves,” said Ralph W. Muller, Chief Executive Officer of Penn’s Health System. “We look forward to also expanding our educational outreach opportunities within the clinical facilities of Bayhealth Medical Center.”

“Our clinical agreement with Bayhealth Cancer Institute permits us to assist in the delivery of high-quality, state-of-the-art care in cancer to the residents of Delaware,” continued Muller. “Through these promising clinical affiliations, we remain committed to the health care needs of the communities Bayhealth serves.”

About Bayhealth Medical Center

Bayhealth Medical Center’s mission is to improve the health status of all members of the Bayhealth community. Southern Delaware’s largest healthcare system, Bayhealth is comprised of Kent General and Milford Memorial Hospitals, Middletown Medical Center and numerous satellite facilities. Bayhealth was ranked Best in Delaware for Cardiac Surgery by HealthGrades and was recognized by J.D. Power and Associates for providing an “Outstanding Inpatient Experience” and an “Outstanding Maternity Experience.” Bayhealth is a technologically advanced not-for-profit healthcare system employing over 2,900 with a medical staff of 455 physicians. In the 2007 fiscal year, Bayhealth recorded 68,731 emergency department visits, 18,825 patients admitted to beds and 2,312 births. Last year, as part of its mission, Bayhealth provided more than $38.5 million in unreimbursed care to patients.

Alion Wins $12.5 Million Audit Services Contract From US EPA

Alion Science and Technology, a provider of employee-owned technology solutions, has won a $12.5 million and four-year contract from the US Environmental Protection Agency to support clean air and environment audits with professional audit services and materials.

Under the contract, Alion will provide the US Environmental Protection Agency (EPA) with audit substances to help the agency verify that its analytical instrumentation is accurate and thoroughly meets the requirements for effective national monitoring programs. Such programs include the national performance audit program, performance evaluation program, clean air status and trends network, chemical specialization network, national air toxics trends network and the stationary source audit programs.

In addition, Alion will provide professional services to assist the EPA with monitoring and testing the analytical systems. Alion’s work will help the EPA to monitor and maintain states compliance with federal regulations that promote a safe environment and clean air.

Chris Amos, senior vice president and manager of technology solutions group at Alion, said: “The auditing and assessing of the public health implications that various pollutants cause in today’s environment is critical to protecting human health. Alion is committed to helping the EPA to ensure safe environments. Alion’s work will help to facilitate the EPA’s mission by providing quality assurance in support of reductions of human exposure to hazardous pollutants.”

Pharmacogenomics Pioneer HairDX Names David Teckman President and CEO

HairDX, LLC (www.hairdx.com), an FDA registered pharmacogenomics research and development company today named David R. Teckman as its new President and CEO. HairDX specializes in testing and genetic analysis of skin disorders and hair biology.

Teckman is a seasoned executive with over 30-years experience in many facets of healthcare. He was recently President and CEO of Sutura, Inc (SUTU) a medical device manufacturer in Orange Country, California where he led a successful turnaround effort.

He went to Sutura after serving as Director of Whitebox Advisors, a $4 billion hedge fund headquartered in Minneapolis, MN. He is currently Chairman of the Board of InstyMeds, a Minneapolis based provider of automated prescription dispensing solutions for acute care settings.

Previously, Teckman was President and CEO of Vivius, a provider of personalized health insurance solutions, President of Disc Systems, a physician practice management software company, Senior Vice President, of PCS Health Systems, a pharmacy benefit management company, Executive Director of Equior Health Plans and National Sales manager of Infomed Corporation.

Teckman is a graduate of Miami University (Oxford, OH) with a Bachelors Degree in Business Administration.

Andy Goren, HairDX former CEO is moving to the role of Chairman & Co-Founder. “By bringing in an industry veteran like David Teckman, HairDX is poised to move forward as an innovator and leader in pharmacogenomics and healthcare research and development,” said Goren.

“The marriage of genetic testing and pharmacological solutions is one of the next new and interesting opportunities in healthcare,” said Teckman. “Like many conditions, hair loss can be determined through early screening and in conjunction with a physician preventative actions can be taken. I am pleased to have the opportunity to join the HairDX team.”

Earlier this year, HairDX became the first company to market genetic tests that predict an individual’s risk for the male or female versions of Androgenetic Alopecia (Hair Loss). The test is available in the US through qualified physicians.

HairDX uses a CLIA certified laboratory (Clinical Laboratory Improvement Amendments) to perform the genetic analysis, offering physicians a powerful screening test for Androgenetic Alopecia before any visible signs of hair loss. The HairDX test results can assist a physician in choosing a course of action as to maintain a patient’s hair.

About HairDX, LLC

HairDX, LLC is a subsidiary of PharmaGenoma, Inc. Based in Irvine, CA, HairDX (www.hairdx.com) HairDX is an FDA registered pharmacogenomics research and development company. HairDX markets the first genetic test for male and female hair loss. The company is dedicated to the research and development of new prescription based therapies tailored to an individual’s genetic make up.

Among HairDX leaders is William V. Murray former Division President of the Molecular Biology Division of Applied BioSystems, Inc., who formerly served in various executive leadership positions within Medtronic, Inc., Andy Goren former CEO of MobileWise, Inc. and GeePS, Inc., David Teckman, former CEO of Sutura, Inc, a medical device company, Professor Doron Lancet, PhD, Head of the Crown Human Genome Center at the Department of Molecular Genetics, Weizmann Institute of Science, Dr Elon Pras, Director of the Institute of Human Genetics, Sheba Medical Center in Tel-Hashomer, Israel, Sharon Keene, MD and President and Medical Director of Physician’s Hair Institute, in Tucson, Arizona and nationally recognized for her pioneering work in the hair transplant field, and Elliott J. Stein, an intellectual property attorney and co-founder of GeePS, Inc.

Is The Ability To Count Innate?

The human ability to count is innate, and is not reliant on numbers or language to express it, according to a team of British and Australian researchers.

Brian Butterworth and colleagues of the Institute of Cognitive Neuroscience at University College London set out to prove that Australian Aboriginal children were able to count even though their languages don’t have number words.

All the groups performed just as well as English-speaking children, researchers reported in the Proceedings of the National Academy of Sciences.

“Recently, an extreme form of linguistic determinism has been revived which claims that counting words are needed for children to develop concepts of numbers above three. That is, to possess the concept of ‘five’ you need a word for five. Evidence from children in numerate societies, but also from Amazonian adults whose language does not contain counting words, has been used to support this claim,” said Butterworth.

“However, our study of aboriginal children suggests that we have an innate system for recognizing and representing numerosities ““ the number of objects in a set ““ and that the lack of a number vocabulary should not prevent us from doing numerical tasks that do not require number words.”

Overall, 45 indigenous Australian children aged between four and seven years were studied from two communities which do not have words or gestures for numbers.

“In our tasks we couldn’t, for example, ask questions such as “ËœHow many?’ or “ËœDo these two sets have the same number of objects?’ We therefore had to develop special tasks,” Butterworth added.

For example, children were asked to put out counters that matched the number of sounds made by banging two sticks together.

“Perhaps the most striking result comes from the cross-modal matching task, where the child has to put out the number of counters corresponding to a sequence of auditory events,” Butterworth said. “This cannot be done using visual memory, but requires the child to generate a mental representation that is abstract enough to serve to represent both auditory and visual enumeration.”

It looks like all the children in the study are using approximate matching to solve the tasks at hand, a strategy which does not rely on the use of number words, said co-author Robert Reeve of the University of Melbourne, Australia.

“Our findings are consistent with the idea that we have an innate system for representing quantity ideas and that the lack of number words in a language should not prevent us from completing simple number and computation tasks,” he added.

Butterworth said: “We’re born with the ability to see the world numerically just as we’re born to see the world in color.”

On the Net:

Thermo Fisher and University Health Network Collaborate in Biomarker Research

Thermo Fisher Scientific has announced a collaboration between its Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry Center and the University Health Network in Toronto to explore uncharted areas in biomarker research.

Led by Eleftherios Diamandis, the project team in Toronto will use Thermo Fisher Scientific’s mass spectrometers, in collaboration with the Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center research team, in an effort to target proteins in cancer cells.

Using Thermo Scientific LTQ Orbitrap and Thermo Scientific Quantum Ultra mass spectrometry systems, Thermo Fisher Scientific said that Dr Diamandis will be the first biochemist to search for biomarker proteins in the secreted fluids of cancer cell lines. He believes this approach will accelerate the validation of biomarkers, targeted assays and, ultimately, the implementation of a reliable blood test for cancers such as breast and colon, among others.

The BRIMS Center and the University Health Network (UHN) will also maintain a cross-validation workflow for the duration of the project to help legitimize new biomarkers that have been validated in Toronto. After the UHN team validates a cancer biomarker, they will send it to the BRIMS Center, which is also equipped with a Thermo Scientific Quantum Ultra mass spectrometer, for a second validation.

Marc Casper, COO of Thermo Fisher Scientific, said: “A central goal of the Thermo Fisher BRIMS Center is to enable and participate in groundbreaking proteomics research that holds promise to make new, potentially lifesaving, discoveries.”

Cardima Receives Market Approval for Thailand: Focus Is on Establishing Centers of Excellence and the Tourist Medicine Market

Cardima, Inc. (OTCBB: CADM), a medical device company focused on the treatment of Atrial Fibrillation (“AF”) and manufacturer of the Cardima’s Surgical Ablation System and the EP Revelation(R) line of therapeutic catheters, has received approval from the Food and Drug Administration, Ministry of Public Health, in Thailand, to market its three main lines of products, including the diagnostic products, the EP therapeutic REVELATION line of products and the Surgical Ablation System.

“The market approval for Thailand is a further step in expanding the commercial potential of Cardima’s products worldwide and is also another significant stride in achieving our ongoing regulatory strategy,” said Robert Cheney, CEO of Cardima. “Thailand is an excellent market for Cardima because of its advanced medical infrastructure and highly trained physicians. Cardima is working closely with Dr. Li Poa of Columbia University Medical School and MEDS Global Healthcare USA in conjunction with Mahidol University and the Thailand Ministry of Health to position Cardima’s products to play a key role in establishing Centers of Excellence in Thailand for the treatment of Atrial Fibrillation.”

Thailand has a leading position globally in the rapidly expanding “Tourist Medicine” market. Dr. Rome Jutabha, a member of the MEDS Global Healthcare USA Advisory Board, commented on the Cardima product approvals, “MEDS Global Healthcare is working closely with Mahidol University and the Thailand Ministry of Public Health to establish several Atrial Fibrillation Centers of Excellence in Thailand. Leading Thai medical centers now treat over 1 million ‘tourist’ patients every year. Thailand wants to leverage their success in this market by focusing on key disease sectors. Atrial Fibrillation represents a huge global market with millions of untreated patients. MEDS Global Healthcare has identified Atrial Fibrillation as a problem requiring treatment resources that cannot currently be provided at adequate levels or at a reasonable cost in most, if not all, developed countries.”

The establishment of Centers of Excellence in Thailand, using Cardima’s Minimally Invasive Surgical System and its other diagnostic and EP ablation therapeutic treatment catheters, will offer patients globally new treatment options with the highest level of care and safety, and at a more reasonable cost. Dr. Jutabha states, “We are very excited to be working with Cardima, Dr. Li Poa, and the physicians at Ramathibodi Hospital on this important initiative.” Dr. Jutabha is an Associate Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles. He is also a member of the internationally renowned CURE Hemostasis Research Group.

Training on the Cardima Surgical Ablation System is expected to commence shortly under the direction of Dr. Li Poa in conjunction with Dr. Suchart Chaiyaroj, Chief of Cardiothoracic Surgery, at Ramathibodi Hospital. This initiative to establish AF Centers of Excellence in Thailand was heavily supported by the cardiology faculty at Ramathibodi Hospital with the significant help of Dr. Khanat Kruthkul. Ramathibodi Hospital is a teaching hospital associated with Mahidol University which is one of the oldest medical schools in Thailand and a highly recognized center for medical training and research.

Dr. Li Poa commented: “We have had great results working with the Cardima minimally invasive Surgical Ablation System. I am excited to introduce this new treatment option to Thailand as part of the program developing AF Centers of Excellence working with MEDS Global Healthcare, Ramathibodi Hospital, leading Thai physicians and the Thai Ministry of Public Health. Atrial Fibrillation is a very large public health issue globally with millions of patients going untreated every year, frustrating both patients and physicians. Treatment, utilizing Cardima’s solutions, needs to be made available to patients. We hope that through the development of these Centers of Excellence in Thailand, patients globally will have one more option in accessing treatment. I have worked with many technologies and products to treat AF, but our first choice for training and patient treatment in Thailand will be Cardima’s.”

Dr. Poa is the Chief of Cardiothoracic Surgery and Cardiac Surgery Program Director at Stamford Hospital, Connecticut; a major teaching affiliate of the Columbia University College of Physicians and Surgeons where he is a faculty member. Dr. Poa specializes in endoscopic cardiac access and the surgical treatment of AF and other minimally invasive techniques.

About Cardima

Cardima, Inc. has developed the PATHFINDER(R), TRACER(R) and VUEPORT(R) Series of diagnostic catheters, the NAVIPORT(R) Series of guiding catheters, the REVELATION(R) Series of ablation catheters, the Surgical Ablation System with its series of ablation probes, and the INTELLITEMP(R) Energy Management Device Series for RF (radiofrequency) energy management. These devices are CE marked and/or received United States FDA 510(k) clearance. The REVELATION Series of ablation catheters with the INTELLITEMP EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) with CE mark approval in Europe; it is not yet commercially approved in the United States.

 Contact:  Dr. Richard Gaston Cardima, Inc. (510) 354-0300 http://www.Cardima.com

SOURCE: Cardima, Inc.

Vyteris Annouces Key Scientific Advisors

Vyteris, Inc. (OTCBB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system and a leader in active transdermal drug delivery technology, announced the formation of a Scientific Advisory Group comprised of four renowned scientists, researchers and clinicians with diverse expertise in active transdermal drug and peptide delivery and central nervous system disorders.

The members of the Scientific Advisory Group are: Russell Potts, PhD, chairperson; Richard Guy, PhD; Randy Mrsny, PhD and Stephen Silberstein, MD, FACP.

“The depth of expertise and breadth of experience of the scientists and practitioners who have joined our Scientific Advisory Group represent key thought leaders in areas important to our field and add extensive pharmaceutical and biomedical experience to Vyteris,” said Haro Hartounian, Ph D., president of Vyteris, Inc. “Their skills and guidance will be invaluable to us as we continue to strive to develop and commercialize new products for active transdermal delivery of pharmaceuticals and specifically peptides.

Notable highlights in the backgrounds of members of the Scientific Advisory Group include:

— Russell Potts, PhD is a recognized expert in the field of iontophoresis. He has published a substantial body of literature, and he is a fellow of the American Association of Pharmaceutical Sciences and the American Institute of Medical and Biological Engineering. He has been involved in the creation of several inventions in the field of iontophoresis and holds more than 25 U.S. patents. He received his Ph.D. in biochemistry from the University of Massachusetts, Amherst, his masters in physical chemistry from Cornell University, and his bachelors in chemistry from Michigan State University. Dr. Potts is also a member of the board of directors at Vyteris;

— Richard Guy, PhD is an internationally renowned expert in the field of iontophoresis and is currently a professor of pharmaceutical science in the Department of Pharmacy and Pharmacology at the University of Bath, United Kingdom. Dr. Guy is also an adjunct professor in the Department of Biopharmaceutical Sciences at the University of California, San Francisco. Dr. Guy received his masters in chemistry from Oxford University and his Ph.D. in pharmaceutical chemistry from the University of London. He is an elected fellow of the Royal Society of Chemistry, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science. He was the first recipient of the Controlled Release Society’s Young Investigator Award in 1988, the same year that he won the British Pharmaceutical Conference Science Award. Dr. Guy was awarded, for his work in iontophoresis, the Prix Applications Medicales de l’Electricite, by the Institut Electricite Sante, Paris, France;

— Randy Mrsny, PhD is currently professor of epithelial biology in the Department of Pharmacy and Pharmacology at the University of Bath, United Kingdom. Dr. Mrsny is also a founder of two biotechnology companies located in the San Francisco Bay Area: Trinity Biosystems and Unity Pharmaceuticals. Previously, Dr. Mrsny headed the drug delivery/biology Group at Genentech, Inc. for 11 years and prior to that, spent three years at ALZA Corporation as the head of peptide biology. Dr. Mrsny received his bachelor’s degree in biochemistry and biophysics at the University of California at Davis and a Ph.D. in anatomy and cell biology at the U.C. Davis School of Medicine; and

— Stephen D. Silberstein, MD, FACP is a professor of neurology at the Jefferson Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania, and director of the Jefferson Headache Center. Dr. Silberstein has been director of the Headache Center since its inception in 1984. He received his doctor of medicine degree in 1967 from the University of Pennsylvania. He trained and did medical research at the National Institutes of Mental Health and has done extensive research and investigational drug studies. There are nearly 200 peer-reviewed articles, book chapters and abstracts resulting from his research. Dr. Silberstein currently serves on the editorial boards of several professional publications including Headache, Topics in Pain Management and Cephalalagia.

The Scientific Advisory Group will meet regularly to provide Vyteris with scientific and clinical guidance for its research, product development, strategic and commercial activities. Additional scientific experts will be consulted with periodically to bring additional capabilities and expertise to assist on the company’s technology and project portfolio.

“I am looking forward to chairing the Scientific Advisory Group, which includes prominent scientists, physicians and opinion leaders,” said Russell Potts, PhD, chairman of the Scientific Advisory Group and a member of Vyteris’ board of directors. “Their experience, perspectives and insights will play an integral role as Vyteris continues to advance its technology and product candidates through pre-clinical and clinical development.”

About Vyteris, Inc.

Vyteris, Inc. is the maker of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris’ proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Vyteris recently announced success in non-invasive delivery of a peptide using its system, where the company demonstrated achievement of therapeutic levels of a peptide without using any needles. For more information, please visit our website at www.vyteris.com.

Vyteris Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,””estimate,””project,””anticipate,””intend,””plan,””may,””will,””could,””would,””should,””believes,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption “Risk Factors” in its most recent Annual Report on Form 10-KSB and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.

Landmark Study Leads to Concern Over the Safety and Cleanliness of MRIs

Peter Rothschild, M.D., renowned Radiologist and MRI expert, has released the ground-breaking paper, recently published on AuntMinnie.com, titled “Preventing Infection in MRI: Best Practices for Infection Control in and Around MRI Suites.” This article expands on the issue that MRIs are often not being properly cleaned, thus leading to concern over Methicillin Resistant Staphylococcus Aureus (MRSA) spread during radiological scans, in particular MRI.

MRSA was originally identified in 1961 and is now widespread throughout healthcare facilities, both hospital and outpatient settings. The most common source for transmission of MRSA is by direct or indirect contact with people who have MRSA infections or are asymptomatic carriers.

A major concern for imaging centers is that MRSA can be carried by asymptomatic patients. Worldwide, it is estimated that up to 53 million people are asymptomatic carriers of MRSA. Of these it is estimated that 2.5 million reside in the United States. Approximately 1% of the U.S. population is colonized with MRSA. Both infected and colonized patients contaminate their environment with the same relative frequency.

The morbidity and mortality of these bacteria is staggering. On average, hospitalizations for the treatment of MRSA versus other infections have a length of stay approximately three times longer and are three times more expensive. Additionally, the risk of death is three to five times greater for patients infected with MRSA versus methicillin sensitive Staph infections.

“Any patient lying on an imaging table could be a carrier capable of contaminating surfaces in the radiology suite,” said Peter Rothschild, M.D., who is attempting to transform the MRI community’s attitude concerning infection control. He adds “MRSA and other pathogens can live on and in common MRI table pads and positioners for periods as long as several months.”

Patients need to ask questions when they go to a hospital or imaging center for an MRI scan. What are the cleaning procedures? How old are the pads? Do the imaging technologists wash their hands between every patient? How do technologists disinfect the MRI table and pads?

“At many MRI centers, there exists a false belief that merely placing a clean sheet over contaminated table pads, without actually cleaning them between patients, will somehow prevent the spread of infectious agents. What is most concerning is that very few MRI centers regularly clean their pads even once a day, much less between patients,” Dr. Rothschild continued. “Additionally, almost all pad sets I have seen in use that are over a few years old are torn or frayed and should have been discarded long ago. It is disgusting to see the terrible conditions of some of the pads that patients come in close contact with in these MRI centers. Old, torn and frayed pads are impossible to properly clean and are a breeding ground for bacteria.”

To combat this potentially lethal public healthcare issue, Dr. Rothschild has developed a technique for determining the safety of pads used in MRI. This technique involves using a magnifying glass to thoroughly examine all the seams for a tear or fraying and the use of a black light to check pads for biological contamination. However, few, if any, MRI centers have adopted these simple safety procedures.

Dr. Rothschild advises, “The best way I have found for patients to protect themselves is to ask to see the center’s written infection control policies before their scans, and visit the center. If there are no written policies I can assure you that infection control has a low priority at that MRI center and I would look for another MRI center where infection control was taken seriously.”

Educating the Public

To request a copy of Dr. Rothschild’s white paper, entitled “Preventing Infections in MRI: Best practices for infection control in and around MRI,” please contact Doug Kohl, Sierra Communications, (209) 586-5887, or [email protected].

About Peter Rothschild, M.D.

Dr. Peter Rothschild is considered one of the world’s foremost Open MRI experts. He formerly served as Medical Director of the research laboratory at the University of California, San Francisco, where he helped develop the first commercially available Open MRI scanner. He is the editor of the first textbook on Open MRI, authored numerous papers on the subject and is a sought after speaker who lectures on MRI and its future. Dr. Rothschild is a Board Certified Radiologist and served as an Adjunct Assistant Professor of Radiology at the University of California at San Francisco. He earned his M.D. degree in 1981 from the University of Louisville, in Louisville, Kentucky. He is founder and president of Patient Comfort Systems Inc., a company dedicated to patient comfort and safety.

 Contact: Doug Kohl Sierra Communications (209) 586-5887 [email protected]

SOURCE: Patient Comfort Systems Inc.

New Survey of 10,000: Nearly Half of Americans Suffer From Seasonal Allergies

JERSEY CITY, N.J., Aug. 19 /PRNewswire/ — Nearly half of all Americans suffer from some type of seasonal allergy, according to QualityHealth.com’s seventh HealthOpin survey. QualityHealth.com is a top ranked consumer health Web site and a main competitor to sites like WebMD and Yahoo!Health.

The survey, which polled 10,006 Americans, primarily women, revealed that 45 percent of Americans suffer from seasonal allergies. Of those who have allergies, 41 percent said they were not tested for allergies until they were in their thirties, 22 percent said they were first tested in their twenties, 15 percent their teens and 22 percent during childhood.

Eighty-two (82) percent of survey respondents with seasonal allergies said they spend fewer than 10 minutes with their doctor during an office visit discussing their prescription allergy medication. Fourteen (14) percent said this discussion lasted between 10 and 20 minutes, three percent said 20 to 30 minutes and one percent typically discuss their prescription allergy medication with their doctor for thirty minutes or more per-visit.

“It’s alarming that so few people with seasonal allergies are spending enough time discussing their medications with their doctors during an office visit,” said Peter Burch, marketing and sales SVP for Marketing Technology Solutions, the owner of QualityHealth.com. “A productive visit with the doctor should be a dialogue in which questions are asked and answered. QualityHealth can be a help in this, as it offers a patient education program called Ask Your Doctor where consumers can get information on their condition and guidance on what to ask the doctor, whether it’s about medication, symptoms or anything else. Armed with the right information, patients will be better able to manage their allergies.”

The survey also showed that twenty-eight (28) percent of seasonal allergies sufferers missed work or school this year directly related to being unable to effectively manage their condition. Eighteen (18) percent of respondents said they typically miss one to three days of work or school each year due to allergy symptoms; seven percent said they miss three to five days; three percent said they miss five to seven days, while 72 percent said they miss no work or school due to allergy symptoms.

As the seventh installment in its “HealthOpin” poll series, QualityHealth.com polled its database of registered members between August 6 and August 10, 2008, collecting responses from 10,006 consumers interested in health matters. Survey respondents were 87 percent female and 13 percent male, with the majority between the ages of 35 and 54. The survey’s margin of error is +/- 3 percent.

About Marketing Technology Solutions

Marketing Technology Solutions (MTS) is a media and technology company specializing in servicing health consumers and advertisers through proprietary algorithms that simultaneously personalize health content and target advertising based on a unique healthographic(TM) consumer profile. Healthographics(TM) are a proprietary combination of demographic and (age, gender, address) and consumers physical and emotional health profile. Our healthographic profile has upward of 250 individual data points. MTS specializes in connecting clients’ brands with health-conscious consumers through data-driven patient education, targeted customer acquisition, syndicated research, and permission-based interactive marketing. MTS gains consumer insights through its network of MTS owned Web sites, QualityHealth.com, Healthpages.com and Nubella.com, whose 10 million members rely on the sites for health and wellness news, tips, tools, support groups, and patient education.

According to July 2008 comScore, Inc., the global leader of measurement in the digital world, QualityHealth.com, with approximately 5.8 million unique visitors per month, ranks among the most visited health sites on the Web.

   For further information, please contact:   For media:                             For investors:   Stephen Gilmore                        Peter Burch   Tel: 212.468.4056                      Tel: 732.491.8043   [email protected]              [email protected]  

Marketing Technology Solutions

CONTACT: media, Stephen Gilmore for Marketing Technology Solutions,+1-212-468-4056, [email protected]; or investors, Peter Burch ofMarketing Technology Solutions, +1-732-491-8043, [email protected]

Web site: http://www.qualityhealth.com/http://www.healthpages.com/http://www.nubella.com/

Garden of Life Introduces The Vitamin Code(TM) As the First All-Raw Multivitamin With Food-Created Nutrients(TM)

WEST PALM BEACH, Fla., Aug. 19 /PRNewswire/ — Garden of Life, Inc., (http://www.gardenoflife.com/) a leading innovator in the Natural Products industry, announced the launch of The Vitamin Code(TM), a groundbreaking dietary supplement line created to change the way Americans take vitamins and minerals forever.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU006 )

Unlike many synthetic multivitamins produced in laboratories, The Vitamin Code (http://www.thevitamincode.com/) formulas are individually cultivated with their unique raw food created nutrients and Code Factors(TM) intact, enabling targeted delivery of nutrients recognized as food by the body. (http://www.youtube.com/watch?v=S8rn6xGONZg) The raw vitamins deliver living enzymes and probiotics and are uncooked, untreated and unadulterated without added binders and fillers. In addition, the vitamins are 100 percent vegan and do not contain any soy allergens, gluten, dairy or fructose.

“The feedback and demand from thousands of health and wellness retailers has been tremendous because there are no other multivitamin products like this on the market,” said Brian Ray, Garden of Life’s president. “Both retailers and consumers are demanding products that go ‘beyond organic,’ so we believe we have hit the mark with the raw vitamins, minerals, and co-factors in The Vitamin Code formulas. We are extremely excited to bring this important new product to market because we feel that raw nutrients and supplementation is the next big thing for the Natural Products industry.”

The Vitamin Code features six targeted formulas: Vitamin Code Women’s formula; Women 50 & Wiser; Vitamin Code Men’s formula; Men 50 & Wiser; Vitamin Code Family formula for adults as well as children six and older; and the Vitamin Code Perfect Weight formula for effective weight management. All ingredients are 100 percent active and have not been subjected to the high heat used in tablet manufacturing.

Validated by scientific research, The Vitamin Code is an exciting discovery linked to a Nobel Prize winner, a determined biochemist, and an escape from the Iron Curtain in the 1950s. Endre “Andy” Szalay, a Hungarian pharmacist, became interested in vitamin research when he sat in on lectures at the University of Szeged by Dr. Albert Szent-Gyorgyi, who won the Nobel Prize in 1937 for discovering vitamin C (ascorbic acid). Szalay dreamed of providing mankind with vitamins and minerals that would not be isolated and synthetic but would be in the ideal form the body could properly utilize. During political and military unrest, he and his family escaped the Iron Curtain during the Hungarian Revolution in 1956.

For more than 30 years, Szalay conducted painstaking experiments to reconnect vitamins and minerals to the food from which they originated. His relentless work resulted in the detection of nutrient-specific peptides unique to each growth organism that allowed for the proper uptake of nutrients for optimal cellular delivery. Szalay finally “cracked” the Vitamin Code and teamed up with Garden of Life to offer consumers the first raw food-created vitamins and minerals.

“We’re excited about this breakthrough development because most consumers have no idea what they’re getting when they purchase a bottle of 200 vitamins for ten dollars in the grocery store,” said Jordan Rubin, founder and CEO of Garden of Life and best-selling author of The Maker’s Diet and 18 other health titles. “People may think they are getting a bargain, but the vast array of nutrients and co-factors that are found in food — and missing from synthetic, highly processed vitamins — could be important for their personal health. The Vitamin Code delivers nutrients in a form that nature provides and that the body thrives upon.”

With a suggested retail price of $39.95 for a 120-count bottle, Vitamin Code vitamins can be purchased nationwide at national chains and independent health food store retailers. In addition, Garden of Life will be partnering with Vitamin Angels to provide vitamins free of charge to children, expectant mothers, and families in need throughout the world. Vitamin Angels (http://www.guidestar.org/) is a non-profit organization dedicated to providing vital nutrition in the form of supplements to developing countries, communities, and individuals in need.

For more information on The Vitamin Code, go to http://www.rawvitamins.com/ . For interviews with health expert and best-selling author Jordan Rubin, contact Rhonda Price at (561) 371-9407.

   CONTACT:  Rhonda Price             [email protected]             (561) 371-9407  

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU006AP Archive: http://photoarchive.ap.org/AP PhotoExpress Network: PRN2PRN Photo Desk, [email protected]

Garden of Life, Inc.

CONTACT: Rhonda Price of Garden of Life, Inc., +1-561-371-9407,[email protected]

Web site: http://www.thevitamincode.com/http://www.gardenoflife.com/http://www.rawvitamins.com/http://www.guidestar.org/

An Essential Report on the Booming Pharma Sector in India Including Its Opportunities and Challenges

Research and Markets (http://www.researchandmarkets.com/research/1fd7d8/booming_pharma_sec) has announced the addition of the “Booming Pharma Sector in India” report to their offering.

India, a US$ 8.2 Billion pharmaceutical market, represents one of the most emerging pharmaceutical markets in the world. According to the latest report “Booming Pharma Sector in India”, in near future, the potential and opportunities within this market will increase by several folds. The market, presently driven by over a billion population, an expanding GDP, and rapid epidemiological transitions, is expected to be the major player in the global pharmaceutical market both in terms of its large domestic market and also as a pharmaceutical export hub.

The research study contains unique market-based research and provides detailed and objective analysis on the Indian pharmaceutical market. It presents a thorough statistical and analytical overview on the Indian pharmaceutical market, and provides past, present and future data on the entire structure, composition and working of the Indian pharmaceutical market. The research extensively discusses the opportunities and challenges that are expected to arise within and from the pharmaceutical market.

Research Highlights

— Between 2007-08 and 2011-12, the Indian domestic pharmaceutical market is expected to grow at a CAGR of nearly 16%.

— The size of the domestic pharmaceutical market is larger than export market. However, owing to the growth of global generics market, stringent price controls in the domestic market, and better margins, the export market is growing much faster than the domestic market.

— Traditional branded generics presently dominate the Indian pharmaceutical market but the future will see strong growth in the specialty branded generics and patented drug segments.

— Drugs for diabetes and cardiovascular diseases are expected to see the fastest growth among all therapy areas during 2007-2011.

— The retail pharmaceutical market in India is presently highly unorganized; however, a vast opportunity exists for the organized market.

— Over the last few years, Cipla, Ranbaxy and GlaxoSmithKline are controlling the top three positions in the Indian pharmaceutical market.

The Report Covers

— Analysis of past, current and future market trends.

— Market study by segment.

— Discussion about the major drivers of the pharmaceutical market.

— Analysis of opportunities created by the market.

— Evaluation of major challenges for the market.

— Review on the government regulations.

— Competitive landscape of the market.

Research Methodology Used

Information Sources

Information has been sourced from books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

Analysis Methods

The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.

 Key Topics Covered: 1. Analyst View 2. Global Pharmaceutical Market 3. India - The Emerging Market 4. India - Macroeconomic & Healthcare Profile 5. Indian Pharmaceutical Market 6. Domestic Pharmaceutical Market 7. Government Regulations & Market Entry 8. Opportunities 9. Roadblocks 10. Profile of Key Players 

Companies Mentioned:

— Ranbaxy Laboratories Limited

— Cipla Limited

— GlaxoSmithKline Pharmaceuticals Limited

— Nicholas Piramal India Limited

— Zydus Cadila

For more information visit http://www.researchandmarkets.com/research/1fd7d8/booming_pharma_sec

Biphasic Defibrillation Does Not Improve Outcomes Compared to Monophasic Defibrillation in Out-of-Hospital Cardiac Arrest

By Freeman, Kimberly Hendey, Gregory W; Shalit, Marc; Stroh, Geoff

ABSTRACT Study Objective. To compare the outcomes of out-of hospital cardiac arrest (OHCA) victims treated with monophasic truncated exponential (MTE) versus biphasic truncated exponential (BTE) defibrillation in an urban EMS system. Methods. We conducted a retrospective review of electronic prehospital and hospital records for victims of OHCA between August 2000 and July 2004, including two years before and after implementation of biphasic defibrillators by the Fresno County EMS agency. Main outcome measures included: return of spontaneous circulation (ROSC), number of defibrillations required for ROSC, survival to hospital discharge, and discharge to home versus an extended care facility. Results. There were 485 cases of cardiac arrest included. Baseline characteristics between the monophasic and biphasic groups were similar. ROSC was achieved in 77 (30.6%, 95% CI 25.2-36.5%) of 252 patients in the monophasic group, and in 70 (30.0% 95% CI 24.5-36.2%) of 233 in the biphasic group (p = .92). Survival to hospital discharge was 12.3% (95% CI 8.8-17%) for monophasic and 10.3% (95% CI 7.0-14.9%) for biphasic (p = .57). Discharge to home was accomplished in 20 (7.9%, 95% CI 5.1-12.0%) of the monophasic, and in 15 (6.4%, 95% CI 3.9-10.4%) of the biphasic group (p = .60). More defibrillations were required to achieve ROSC (3.5 vs. 2.6, p = .015) in the monophasic group. Conclusions. We found no difference in ROSC or survival to hospital discharge between MTE and BTE defibrillation in the treatment of OHCA, although fewer defibrillations were required to achieve ROSC in those treated with biphasic defibrillation. Key words: cardiac arrest; defibrillation; emergency medical services; Utstein template

PREHOSPITAL EMERGENCY CARE 2008;12:152-156

INTRODUCTION

Electrical defibrillation is one of the most important medical interventions in the care of patients with cardiac dysrhythmias. It is one of the only prehospital interventions that has been shown to improve survival after cardiac arrest. The standard form of defibrillation for many years has been the delivery of electrical energy with a monophasic waveform. More recently, the biphasic waveform has been touted as achieving similar if not better rates of conversion, while using less energy.1-7 Most human studies comparing the two modes have been in the controlled setting of a cardiac catheterization lab, during electrophysiologic studies, or defibrillator implantation. A meta-analysis of such trials found that biphasic waveforms at 150-200 joules were as effective as monophasic waveforms at 200-360 joules at terminating episodes of ventricular tachycardia or fibrillation.8 In one prospective study of prehospital cardiac arrest, ventricular fibrillation was terminated with similar efficacy with lower energy biphasic defibrillation as compared to escalating energy monophasic defibrillation. However, survival to hospital arrival or discharge was not evaluated.9 In a recent randomized, controlled trial analyzing the two waveforms delivered at the same energy of 200-360 joules for out-of-hospital cardiac arrest (OHCA) ventricular fibrillation (VF), no statistically significant difference was found in the endpoints of admission alive to the hospital, return of spontaneous circulation (ROSC), survival, and neurologic outcome.10

Biphasic defibrillators have become the industry standard for most manufacturers, and emergency medical service (EMS) providers and hospitals are in the process of replacing monophasic units with newer biphasic models. However, outcome studies for this newer mode of defibrillation have not been widely performed, particularly in the prehospital arena, where it is being increasingly utilized.6

Our goal was to use a “before and after” methodology to compare the success rate of biphasic defibrillation to that of monophasic defibrillation, by: 1) determining the percentage of patients who experienced ROSC, 2) determining the percentage of patients who survived to hospital discharge, 3) evaluating hospital discharge destination, whether to home or extended-care facility, as a surrogate indicator of neurological outcome, and 4) assessing number of attempts required for successful defibrillation.

MATERIALS AND METHODS

Study Design

This investigation was a retrospective case review study of out- of-hospital cardiac arrest victims who were treated with defibrillation by American Ambulance Advanced Life Support (ALS) providers in Fresno County between August 1,2000 and July 31,2004. This study was approved by the Community Medical Centers Institutional Review Board with informed consent by subjects waived.

Setting

The study setting was a mixed urban and suburban region, with a metropolitan population of 500,000 and county population of approximately 1 million. A single private ambulance company provided the majority of out-of-hospital emergency medical services and generated electronic records of all patient encounters.

Selection of Participants

Patients were included if they were at least 18 years of age, suffered nontraumatic out-of-hospital cardiac arrest, and were treated with defibrillation or cardioversion by out-of-hospital ALS providers.

Interventions

In August 2002, all defibrillators were switched from the monophasic truncated exponential (MTE) waveform MRL 360 SLX Monitor and DC Defibrillator (Medical Research Laboratories, Buffalo Grove, IL) to the biphasic truncated exponential (BTE) waveform Zoll M Series Monitor (Zoll Medical Corporation, Chelmsford, MA). Protocols for the treatment of cardiac arrest remained unchanged, except that escalating energies from 200-360 joules were used with the MTE defibrillators, while escalating energies from 150-200 joules were used with BTE defibrillators.

Data Collection and Processing

Data collected from out-of-hospital electronic records included 911 call-response interval, call-shock interval, patient age, sex, presenting rhythm, presence of bystander cardiopulmonary resuscitation (CPR), type of defibrillator, number of defibrillations, defibrillation energy in joules, ROSC, and transport destination. The call-response interval is defined as the time from 911 call receipt to time of arrival on scene, and call- shock interval is defined as the time from call receipt to time of first defibrillatory shock. This format is consistent with Utstein reporting guidelines.11 Hospital records were reviewed to determine survival to discharge and discharge destination. We also obtained records of deaths reported to the county coroner’s office.

Outcome Measures

The primary outcome measures were ROSC after treatment with defibrillation, number of defibrillatory shocks required to achieve ROSC, and survival to hospital discharge. Since formal cognitive and functional testing was not available for most patients, we used the discharge disposition, whether to home or to an extended-care facility, as a surrogate marker of neurologic outcome.

Primary Data Analysis

Between-group comparisons of times, treatments, and outcomes were conducted using f-tests and Fisher’s exact tests available online (http://graphpad.com/ quickcalcs), with an alpha of 0.05, and statistical comparisons were reviewed by a statistician. Because our sample size was determined by the number of cases that occurred during a specified time interval, we did not perform an a priori power calculation. However, we did perform a post-hoc power calculation to address the possibility of type II error (http:// www.dssresearch.com/toolkit/spcalc/power _p2.asp).

RESULTS

Characteristics of Study Subjects

A total of 485 cases of out-of-hospital cardiac arrest met the inclusion criteria and had electronic out-of-hospital records available during the study period. Two hundred fifty-two of these patients were treated with MTE defibrillation and 233 of these patients were treated with BTE defibrillation. The age, gender, and presence of bystander CPR were similar between the MTE and BTE groups (Table 1). The call-response intervals and call-shock intervals were also similar between the two groups, but there was a trend toward shorter biphasic call-response and call-shock intervals when only those patients presenting in ventricular tachycardia (VT) or VF were considered (Table 1). The proportion of patients whose initial arrest rhythm was VT or VF was also similar between groups (Table 1).

Main Findings

Seventy-seven (30.1%, 95% CI 25.2-36.5%) of the 252 patients who were treated with MTE defibrillation achieved ROSC. Similarly, 70 (30.0% 95% CI 24.536.2%) of the 233 patients who were treated with BTE defibrillation achieved ROSC (p = .92) (Fig. 1). A similar number of patients, 31 (12.3%, 95% CI 8.8-17%) of the MTE group and 24 (10.3%, 95% CI 7.0-14.9%) of the BTE group, were discharged alive from the hospital (p = .57). Discharge to home was also unchanged and was accomplished in 20 (7.9%, 95% CI 5.1-12.0%) of the MTE patients and in 15 (6.4%, 95% CI 3.9-10.4%) of the BTE group (p = .60). The remainder of the surviving patients were discharged to extended care facilities (Fig. 1). We were unable to locate hospital or coroner data for 18 patients.

The mean number of total shocks delivered was significantly higher in those treated with MTE defibrillation (4.3 shocks, 95% CI 3.9-4.7) than BTE defibrillation (2.9 shocks, 95% CI 2.6-3.1, p = 0.001). Patients who achieved ROSC also required more shocks in the monophasic group with a mean total of 3.5 (95% CI 2.94.1) than in the biphasic group with a mean total of 2.6 (95% CI 2.1-3.0, p = 0.015) (Table 2). A post-hoc power calculation revealed that with our sample size and an alpha of 0.05, the study had a power of 74.7% to detect an absolute increase of 10% in ROSC, 89.9% to detect a 10% increase in survival to discharge, and 46.4% to detect a 5% increase in survival to discharge.

DISCUSSION

We found that BTE defibrillation was no more efficacious than MTE defibrillation in the out-of-hospital setting for achieving ROSC or survival to hospital discharge. Although fewer shocks were necessary with BTE defibrillation, the rate of ROSC, hospital discharge, and discharge to home were not improved. Others have similarly failed to demonstrate a survival benefit for biphasic defibrillation.10,12-15 White et al. found no difference in return of spontaneous circulation (ROSC) or discharge home.9 Morrison et al. enrolled all nontraumatic out-of-hospital cardiac arrest victims presenting in VF or VT treated with defibrillation and found improved biphasic shock efficacy compared to monophasic efficacy, but, again, no improvement in ROSC or survival to hospital discharge.16 Most recently, Kudenchuk et al. prospectively randomized OHCA VF victims to monophasic dampened sine (MDS) or BTE waveform defibrillation and found no difference in hospital admission, hospital discharge, ROSC, and neurologic outcome.10

Fewer defibrillatory shocks and lower energy requirements to achieve ROSC in BTE defibrillation has been consistently reported in other studies.12-16 Schneider and Stothert also found a greater percentage of ROSC in their biphasic groups, compared to monophasic.12,14 However, our study, like those of Van Elam, Morrison, and Kudenchuk, found no difference in ROSC or survival between groups.10,13,16

Biphasic monitors have a practical advantage of being smaller and lighter devices. There is also a theoretical advantage to using less energy and possibly causing less myocardial stunning or damage during resuscitation.17,18 Less myocardial damage should theoretically translate to superior clinical outcomes, although this potential advantage has not yet been demonstrated.10,12-15 Several studies of postresuscitation myocardial injury have indicated that low-energy shocks may produce less injury and dysfunction.8,17,19 However, this finding has not been consistent, and other studies have shown no difference in postresuscitation myocardial dysfunction.1,19,20 Regardless, we did not find any superiority of biphasic defibrillation over monophasic defibrillation with respect to ROSC or survival to hospital discharge. Biphasic defibrillation has prematurely been promoted as an exceptional tool to assist in resuscitation, but evidence of improved patient outcomes has been lacking. In an environment where the costs of medical care are skyrocketing, smaller EMS systems may not have the financial resources to “upgrade” to newer biphasic equipment but may feel pressure to do so. The literature to date suggest that such pressure is unwarranted and premature.

Limitations

There were several limitations of our study. First, the design was retrospective, which raises the possibility of important baseline differences between the two study groups. This design could have biased our results in either direction. Also, there were missing data points in some EMS and hospital records. Most importantly, we could find no hospital or coroner data on 18 patients. A large difference in survival in this group of patients could have significantly changed the results of our study. However, this subgroup was very similar to the rest of the study group in age (mean, 63 years), gender (56% male), and ROSC (27.8%). If all five patients with ROSC who were lost to follow-up survived to hospital discharge, there still would have been no significant difference in survival between the monophasic and biphasic groups.

A second limitation was that we only included cases from the private ambulance company serving most of the county because this company generated an electronic EMS record. Our design excluded the small percentage of patients in our system transported by small providers using paper records. Although our data include the large majority of urban and rural patients in our area, the excluded patients were all from the rural setting. However, it seems unlikely that any bias introduced by excluding this small subgroup would have altered our results, given previous reports demonstrating poorer outcomes with long prehospital response and transport times.9

Third, the majority of patients who were transported to a hospital were taken to one of five local facilities. Although each of the five hospitals had intensive care capabilities, outcomes may have differed by hospital. Our numbers were too small to allow for meaningful subgroup analysis by various hospitals, but even if there were significant overall survival differences between the hospitals, the differences would likely affect both the biphasic and monophasic groups equally. Also, there were no major changes in the care of cardiac arrest survivors during the study period, with none of the local hospitals adopting the routine use of hypothermia.

Fourth, we did not use a rigorous definition or formal determination of favorable neurologic outcome. Instead, we used discharge to home or to an extended care facility. Most patients discharged home were noted to be alert and ambulatory, and likely had more favorable neurologic outcomes than those discharged to extended care facilities, but no formal assessments were done. Again, this method would have likely biased equally between MTE and BTE defibrillation toward more favorable outcomes overall.

Fifth, only BTE and MTE waveforms were analyzed. Given evidence that rectilinear biphasic and monophasic dampened sine waveforms may produce different results, the results of this study cannot be extrapolated to those waveforms.

Finally, we did not examine whether the number of shocks or amount of energy used conferred a functional advantage to survivors of cardiac arrest in terms of left ventricular dysfunction, congestive failure, or longterm survival.

CONCLUSION

We found no difference in ROSC or survival to hospital discharge between monophasic and biphasic defibrillation in the treatment of OHCA, although fewer defibrillations were required to achieve ROSC in those treated with biphasic defibrillation.

We thank Brandy Snowden (research coordinator), Luke Wright, Brandi Martin (research assistants), Erik Peterson, Donna Hankins, American Ambulance, and Ronna Mallios (statistician) for their invaluable assistance with this project.

References

1. Niemann JT, Burian D, Garner D, Lewis RJ. Monophasic versus biphasic transthoracic countershock after prolonged ventricular fibrillation in a swine model. J Am Coll Card. 2000;36:932-938.

2. Leng CT, Paradis NA, Calkins H, et al. Resuscitation after prolonged ventricular fibrillation with use of monophasic and biphasic waveform pulses for external defibrillation. Circulation 200;101:2968-2974.

3. Szili-torok T, Theuns D, Verblaauw T, et al. Transthoracic defibrillation of short-lasting ventricular fibrillation: a randomised trial for comparison of the efficacy of low-energy biphasic rectilinear and monophasic damped sine shocks. Acta Cardiol. 2002;57(5):329-334.

4. Higgins SL, Herre JM, Epstein AE, et al. A comparison of biphasic and monophasic shocks for external defibrillation. Prehosp Emerg Care 2000;4:305-313.

5. Higgins SL, O’Grady S, Banville I, et al., Efficacy of lower energy biphasic shocks for transthoracic defibrillation: a follow- up clinical study. Prehosp Emerg Care 2004;8:262-267.

6. White RD. Waveforms for defibrillation and cardioversion: recent experimental and clinical studies. Curr Opin Crit Care 2004;10:202-207.

7. Hong MF, Dorian P. Update on advanced life support and resuscitation techniques. Curr Opin Cardiiol. 2004;20:1-6.

8. Faddy SC, Powell J, Craig J. Biphasic and monophasic shocks for transthoracic defibrillation: a meta-analysis of randomized controlled trials. Resuscitation 2003;58:9-16.

9. White RD, Hankins DG, Atkinson EJ. Patient outcomes following defibrillation with a low energy biphasic truncated exponential waveform in out-of-hospital cardiac arrest. Resuscitation 2001;49:9- 14.

10. Kudenchuk PJ, et al. Transthoracid incremental monophasic versus biphasic defibrillation by emergency responders (TIMBER). Circulation 2006;114:2010-2018.

11. Task force of representatives from the European Resuscitation Council, American Heart Association, Heart and Stroke Foundation of Canada, Australian Resuscitation Council. Recommended guidelines for uniform reporting of data from out-of-hospital cardiac arrest: the “Utstein style.” Resuscitation 1991;8:1-26.

12. Schneider, T, Martens, PR, Paschen, H, et al. Multicenter, randomized, controlled trial of 150 J biphasic shocks compared with 200- to 360-J monophasic shocks in the resuscitation of out-of- hospital cardiac arrest victims. Optimized Response to Cardiac Arrest (ORCA) Investigators. Circulation 2000;102:1780-1787.

13. Van Alem AP, et al. A prospective, randomized, and blinded comparison of first shock success of monophasic and biphasic waveforms in out-of-hospital cardiac arrest. Resuscitation 2003;58:17-24.

14. Stothert JQ Hatcher TS, Gupton CL, et al. Rectilinear biphasic waveform defibrillation of out-of-hospital cardiac arrest. Out-ofHospital Emerg Care 2004;8:388-392.

15. Carpenter J, et al. Defibrillation waveform and post-shock rhythm in out-of-hospital ventricular fibrillation cardiac arrest. Resuscitation 2003;59:189-196.

16. Morrison, L, Dorian, P, Long, J, et al. Out-of-hospital cardiac arrest rectilinear biphasic to monophasic damped sine defibrillation waveforms with advanced life support intervention trial (ORBIT). Resuscitation 2005;66:149-157. 17. Tang W, Weil MH, Sun S, et al. A comparison of biphasic and monophasic waveform defibrillation after prolonged ventricular fibrillation. Chest 2001;120:948-954.

18. Jones JL, Tovar OH. Electrophysiology of ventricular fibrillation and defibrillation. Crit Care Med. 2000;28(Suppl.):N219- N221.

19. White RD. New concepts in transthoracic defibrillation. Emerg Med Clin N Am. 2002;20:785-807.

20. Walcott GP, Killingsworth CR, Ideker RE. Do clinically relevant transthoracic defibrillation energies cause myocardial damage and dysfunction? Resuscitation 2003;59:59-70.

Kimberly Freeman, MD, Gregory W. Hendey, MD, Marc Shalit, MD, Geoff Stroh, MD

Received July 12,2007 from the Department of Emergency Medicine, UCSF-Fresno, Medical Education Program, Fresno, California. Accepted for publication November 2, 2007.

No external support or outside financial interest contributed to this study.

Address correspondence and reprint requests to: Gregory W. Hendey, MD, FACEP, UCSF-Fresno, Emergency Medicine, Medical Education Program, 155 North Fresno Street, Fresno, CA 93701-2302. e- mail: [email protected].

doi: 10.1080/10903120801907240

Copyright Taylor & Francis Ltd. Apr-Jun 2008

(c) 2008 Prehospital Emergency Care. Provided by ProQuest LLC. All rights Reserved.

Triathlon Success for Vernon, 63

By Emma Judd

At the age of 63, most people are counting down the last couple of years until retirement.

Not so Vernon Steadman, who decided in his 63rd year to complete the arduous London Triathlon.

Instead of putting his feet up and watching the Olympics, the surveyor from Penclawdd spent last Sunday swimming 1,500 metres in London’s Royal Docks, riding 40 kilometres and finally running 10 kilometres.

It was a follow-on event from a decade ago, when Mr Steadman took part in a shorter, faster, sprint triathlon.

“A lot of people said I’ve done it the wrong way round – I should have done the sprint triathlon this time round.

“I just wanted to prove to myself that aged 63 I still had gas in the tank, as it were, to prove to myself that I could still hack it.

“I also did it to motivate others in the family, to say if the old man can do it, get off your backside.”

A side effect of the training, he said, was shedding two stone in two months.

Mr Steadman also used the challenge to raise money for the Kids Get Going charity, which provides sporting wheelchairs for disabled youngsters.

He said: “The final amount hasn’t been quantified because it’s still coming in, but it’s probably around pounds500.

“It’s not too bad. Trying to fit in training in the evenings and working, I must admit the fund-raising took a bit of a back seat until the final two weeks leading up to the triathlon. I also wanted to make sure I’d be able to do it.”

Mr Steadman said his family had been very supportive of his endeavour, lending and giving him equipment on which to train and use in the competition, including a bike, running shoes, and vests.

“They were concerned about me while I was doing it,” he said.

“They kept ringing my wife during the course of it – they thought I was either going to drown or flake out!” But instead of doing either of those things, Mr Steadman completed the course.

And he did it in three hours, 30 minutes.

“I’ll definitely be doing it again next year,” he said.

(c) 2008 South Wales Evening Post. Provided by ProQuest LLC. All rights Reserved.